Guidelines for treatment of renal injury during cancer chemotherapy 2016 by Horie Shigeo et al.
Guidelines for treatment of renal injury
during cancer chemotherapy 2016
著者 Horie Shigeo, Oya Mototsugu, Nangaku Masaomi,
Yasuda Yoshinari, Komatsu Yasuhiro, Yanagita
Motoko, Kitagawa Yuko, Kuwano Hiroyuki,
Nishiyama Hiroyuki, Ishioka Chikashi, Takaishi
Hiromasa, Shimodaira Hideki, Mogi Akira, Ando
Yuichi, Matsumoto Koji, Kadowaki Daisuke, Muto
Satoru
journal or
publication title
Clinical and experimental nephrology
volume 22
number 1
page range 210-244
year 2018-02
権利 (C) The Author(s) 2017. This article is an
open access publication
This article is distributed under the terms of
the Creative Commons Attribution 4.0
International License (http://crea
tivecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution, and
reproduction in any medium, provided you give
appropriate credit to the original author(s)
and the source, provide a link to the Creative
Commons license, and indicate if changes were
made.
URL http://hdl.handle.net/2241/00151224
doi: 10.1007/s10157-017-1448-z
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
GUIDELINE
Guidelines for treatment of renal injury during cancer
chemotherapy 2016
Shigeo Horie1,2 • Mototsugu Oya3 • Masaomi Nangaku4 • Yoshinari Yasuda5 •
Yasuhiro Komatsu6 • Motoko Yanagita7 • Yuko Kitagawa8 • Hiroyuki Kuwano9 •
Hiroyuki Nishiyama10 • Chikashi Ishioka11 • Hiromasa Takaishi12 •
Hideki Shimodaira13 • Akira Mogi9 • Yuichi Ando14 • Koji Matsumoto15 •
Daisuke Kadowaki16 • Satoru Muto1,2
Published online: 30 August 2017
 The Author(s) 2017. This article is an open access publication
1. Introduction
Advances in cancer drug therapy have led to improvements
in the outcomes of cancer patients, as well as increasing
numbers of patients undergoing anticancer chemotherapy
and molecularly targeted drug therapy. One adverse event
associated with cancer drug therapy is nephrotoxicity,
which impedes effective cancer therapy and diminishes the
quality of life of cancer patients. Consequently, onco-
nephrology has emerged as a new clinical field concerned
with the management of nephrotoxicity in cancer drug
therapy, creating expectations for advanced expertise and
the accumulation of accurate evidence. However, while
patients with renal impairment have heretofore undergone
planning regarding administration of cancer drug therapy,
procedures for nephropathy prevention, and measures for
treatment of drug-induced nephrotoxicity in clinical set-
tings based on tradition, experimental rules, and informa-
tion from clinical trials, the soundness of the evidence for
these practices has been uncertain.
Over the past 10 years, estimated glomerular filtration
rate (eGFR) has replaced creatinine clearance in the
assessment of renal function; in addition, research has
revealed the pathologies of and risk factors for chronic
kidney disease (CKD) and acute kidney injury (AKI). The
objectives of the guidelines presented here are to support
improvements in the results of cancer drug therapy and the
quality of life of cancer patients through application of
these advances in clinical nephrology and the practice of
evidence-based treatment.
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For these guidelines, we have assembled a group of
Japanese experts on cancer drug therapy and nephrology to
select highly important clinical questions that are fre-
quently encountered in everyday practice. These guidelines
ultimately comprise 16 clinical questions in two chap-
ters regarding assessment of renal function and prevention
of nephropathy during cancer drug therapy, thereby
determining the level of evidence to support clinical
assessments and elucidating the nature of current standard
treatments. However, in drafting these guidelines, we dis-
covered a number of clinical issues (evidence gaps)
regarding cancer drug therapy and renal impairment. For
example, 1) there is very little clinical research on cancer
drug therapy and nephropathy to begin with; 2) many
clinical trials continue to use creatinine clearance to assess
renal function; 3) in assessments of renal function in large
populations, there is a vast discrepancy between eGFR and
measured values of GFR; and 4) it remains unknown
whether body surface area corrections of drug doses are
appropriate for elderly patients (who have reduced muscle
mass) or obese patients. These and other evidence gaps
must be resolved for the sake of future research.
These guidelines were drafted with reference to the
‘‘Minds Treatment Guideline Creation Companion 2014’’
using the Minds Guideline Creation support tool
‘‘GUIDE’’. We would like to express our profound grati-
tude to Doctors Tsuguya Fukui and Takeo Nakayama of
Minds for their roles as advisors in the creation of our
guidelines.
We would also like to take this opportunity to express
our appreciation to the many young physicians of the
systematic review team for their contributions in drafting
structured abstracts.
The primary significance of treatment guidelines is their
application in daily clinical practice. We would appreciate
any criticisms or ideas that would be useful in future
revisions of these guidelines.
Shigeo Horie, M.D.
Professor and Chairman,
Department of Urology
Juntendo University, Graduate School of Medicine
2. On the Occasion of Publication
Cancer has been the leading cause of death among Japanese
people for many years; currently, cancer is responsible for
approximately 30% of all deaths in Japan. As the Japanese
population ages, this figure will continue to increase year
after year. Therefore, further development of treatment
measures against cancer is undoubtedly one of the most
crucial issues for the Japanese population. One such measure
is drug therapy, which is widely performed. Many anticancer
drugs are strongly associated with effects on various organs;
a sufficient understanding of these associations is a prereq-
uisite for effective and successful cancer drug therapy.
Unfortunately, there have been no guidelines regarding
cancer drug therapy in relation to associations with indi-
vidual organs. Medical staffs and individuals involved in the
treatment of cancer have a great interest for the relevance of
the anti-cancer agent and a kidney. However, no previous
guidelines exist that systematically described the association
between cancer drug therapy and the kidneys.
In addition to chronic kidney disease, the concept of
acute kidney injury has rapidly become widespread in
recent years. As renal function assessment methods and
biomarkers continue to develop, evolutions in nephropathy
concepts are being observed.
Against this backdrop, the Japanese Society of
Nephrology, the Japan Society of Clinical Oncology, the
Japanese Society of Medical Oncology, and the Japanese
Society of Nephrology and Pharmacotherapy have jointly
published the ‘‘2016 Guidelines for the Treatment of
Nephropathy in Cancer Pharmacotherapy’’; the timely and
fascinating publication of these guidelines marks a major
step in the development of cancer pharmacotherapy. This is
truly a document that individuals involved in cancer
treatment have long awaited. I sincerely hope that this
document will be used appropriately and effectively by all
individuals who work on cancer treatment.
Lastly, I would like to express my deep gratitude to
everyone involved in the drafting of these guidelines.
Seiichi Matsuo, MD. PhD.
President, Japanese Society of Nephrology
(President, Nagoya University)
As the Japanese population continues to age, physicians
engaged in cancer pharmacotherapy increasingly encounter
patients with organ dysfunction due to comorbid diseases;
however, there is a lack of information regarding appro-
priate cancer pharmacotherapy for cancer patients with
comorbid nephropathy. Currently, package inserts for the
majority of anticancer drugs contain no clear information
regarding administration in patients with chronic kidney
disease. Although nephropathy is a major adverse event
elicited by cancer pharmacotherapy, regimens for the pre-
vention of nephropathy are currently modified based on the
experience of individual physicians and the customs of
individual facilities.
The present guidelines begin with renal function
assessment methods necessary for determining doses of
anticancer drugs, followed by descriptions of supportive
therapy during cancer pharmacotherapy with cisplatin and
other drugs for patients with decreased renal function. The
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guidelines also discuss supportive therapy for maintenance
dialysis patients and patients with specific comorbidities. I
believe that these guidelines will prove useful in daily
clinical practice.
As part of its duties as a multidisciplinary academic
society, the Japan Society of Clinical Oncology has been
engaged in the formulation of guidelines for common
supportive therapies for the treatment of cancer of various
organs. Our society considers it greatly significant to have
had the opportunity to participate in the formulation of
these guidelines, which will contribute to improvements in
the quality of treatment for patients with renal impairment.
Lastly, I would like to express my profound gratitude to
Doctor Shigeo Horie, President of the Guideline Prepara-
tion Committee, for his tireless leadership in the drafting of
these guidelines, as well as the many others who devoted
their efforts to drafting the guidelines.
Yuko Kitagawa, M.D., Ph.D., F.A.C.S.
Chairman of Board of Directors, Japan Society of Clinical
Oncology
Professor and Chairman, Department of Surgery, Keio
University School of Medicine
Cancer is reported to afflict one in every two Japanese
people and kill one in every three. As the Japanese popu-
lation continues to age, the number of elderly cancer
patients is likely to continue to increase. Consequently, an
increase is also expected in the number of cancer patients
with comorbidities such as nephropathy.
In the use of anticancer drugs for cancer patients with
nephropathy, consideration must be given to the possibility of
the enhancement of adverse events owing to diminished
excretion, as well as the possibility that the toxicity of anti-
cancer drugs will exacerbate nephropathy. However, as effec-
tive anticancer drugs are not used based solely on comorbid
nephropathy, the therapy cannot be considered appropriate.
The performance of cancer pharmacotherapy in patients
with nephropathy requires knowledge of not only oncol-
ogy, but also nephrology. I believe that the joint creation of
these guidelines by the Japanese Society of Nephrology,
kidney specialists with the Japanese Society of Nephrology
and Pharmacotherapy, and cancer therapy specialists with
the Japan Society of Clinical Oncology is incredibly
important and significant for the performance of appro-
priate pharmacotherapy in cancer patients with nephropa-
thy. These guidelines establish crucial clinical questions
and provide clear descriptions about these questions.
I anticipate that these guidelines will be utilized effec-
tively by physicians, pharmacists, and nurses throughout
Japan, and that they will be useful in the performance of
appropriate anticancer drug therapy in cancer patients with
nephropathy.
Yuichiro Ohe
National Cancer Center Hospital Department of Thoracic
Oncology
The Japanese Society of Nephrology and Pharmacotherapy
strives to foster ‘‘medical professionals who responsibly offer
effective, safe, and the most appropriate drug therapy optimized
to the individual patient’’. Since the society was founded, it has
worked toward fulfilling the following four major objectives: 1)
to ensure the proper use of drugs and prevention of toxic side
effects in patients with decreased renal function, 2) to prevent
renal function deterioration and cardiovascular complications
through proper medication guidance, 3) to provide appropriate
drug therapy to dialysis patients with complications, and 4) to
prevent drug-induced renal damage caused by nephrotoxic
agents and drugs inducing renal ischemia. The Japanese Society
of Nephrology and Pharmacotherapy was granted the oppor-
tunity to create the ‘‘2016 Guidelines for the Treatment of
Nephropathy in Cancer Pharmacotherapy’’ alongside the
Japanese Society of Nephrology, the Japan Society of Clinical
Oncology, and the Japanese Society of Medical Oncology. The
joint creation of these guidelines aligns with our own society’s
goals, filling me with profound pride.
Similar to antibacterial agents and nonsteroidal anti-in-
flammatory drugs (NSAIDs), anticancer drugs can easily
cause drug-induced nephropathy. The renal function of a
patient receiving anticancer drugs fluctuates easily due to the
effects of various factors such as the patient’s condition,
activity level, and age. Anticancer drug pharmacokinetics,
anticancer drug interactions, and conceptions of patients’
renal function are the fortes of our society, which specializes
in nephrology and pharmacotherapy. In order to exert our
specialized capacity, we recently established a Committee for
the Formulation and Drafting of Guidelines. Going forward,
with this committee at the center of our efforts, we hope to use
our specialized perspective in relation to nephrology and
pharmacotherapy to contribute to the drafting and revision of
various types of practice and therapeutic guidelines.
In conclusion, I earnestly hope that the use of these
guidelines will lead to the implementation of safer, more
effective cancer drug therapy in all medical care settings
through the prevention of anticancer drug-induced irre-
versible nephropathy, as well as the reduction and pre-
vention of side effects, achieved by the establishment of
appropriate dosages for patients with decreased renal
function, including elderly patients.
Sumio Hirata,
President of the Japansese Society of Nephrology and
Pharmacotherapy.
Professor and Director, Division of Clinical Pharmacology,
Center for Clinical Pharmaceutical Sciences, Faculty of
Pharmaceutical Sciences, Kumamoto University
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3. Background
Nephropathy is a major potential adverse event in cancer
drug therapy. Anticancer chemotherapy, particularly in
patients with comorbid chronic kidney disease, requires
sufficient examination of the balance of the potential
therapeutic benefit with the risk of decreased renal func-
tion. However, cancer drug therapy in clinical settings has
been performed based solely on physicians’ experience and
instincts, a situation that calls for evidence-based
guidelines.
The objective of the present guidelines was to draft
clinical questions (CQs) and recommendations for those
CQs to be specifically applied in real-world clinical prac-
tice. The overwhelming diversity of drugs used to treat
cancer involves equally diverse nephropathy pathologies
and dose adjustments. In establishing CQs, we have
attempted be as comprehensive as possible. These guide-
lines take into account consistency with not only existing
guidelines, but also guidelines on acute kidney injury
treatment currently under production (Japanese Society of
Nephrology, Japanese Society for Dialysis Therapy, Japan
Society for Blood Purification in Critical Care, Japanese
Society of Intensive Care Medicine, Japanese Society for
Pediatric Nephrology, etc.).
In 2016, Japanese Society of Nephrology, Japan Society
of Clinical Oncology, Japanese Society of Medical
Oncology, and The Japanese Society of Nephrology and
Pharmacotherapy established the Committee Of this
guideline drafting group, which published Guidelines for
treatment of renal injury during cancer chemotherapy
2016 in Jpn J Nephrol. 2016; 58:985-1050. This is the
English version of that report. Chairman: Shigeo Horie.
4. Guideline objectives, assumed users, and social
significance
This document includes guidelines regarding nephropathy
in patients undergoing cancer drug therapy. These guide-
lines are intended to serve as a basis for assessing CQs that
are likely to be frequently encountered in daily practice;
they have been written for physicians, pharmacists, nurses,
and all other medical personnel engaged in the treatment of
cancer. The objective of the development of these guide-
lines was to support clinical assessments by obtaining
answers as specific as possible regarding questions
encountered in real-world practice by cancer specialists in
order to convey current standard views and specifics of
practice. However, we ultimately treat not cancer, but
rather cancer patients; rather than performing individual
medical acts uniformly, treatment should sufficiently
respect each patient as an individual.
It is hereby specified that these guidelines do not contain
assessment criteria for medical disputes or medical
lawsuits.
5. Patients targeted by the guidelines
These guidelines are intended for the treatment of all adult
cancer patients and not for pediatric cancer patients. The
target of these guidelines is nephropathy directly caused by
cancer drug therapy; the guidelines do not apply to, for
example, nephropathy resulting from other causes in long-
term cancer survivors.
6. Administrative framework
The drafting of these guidelines is characterized pri-
marily by the participation of members from four dif-
ferent academic societies: the Japanese Society of
Nephrology, the Japan Society of Clinical Oncology, the
Japanese Society of Medical Oncology, and the Japanese
Society of Nephrology and Pharmacotherapy. The
drafting of these guidelines brought together nearly all of
the principal groups currently engaged in cancer treat-
ment and kidney disease in Japan, thereby allowing us to
integrate all views currently standard in Japan. Further-
more, these guidelines were drafted in reference to the
‘‘Minds Treatment Guideline Creation Companion
2014’’ using the Minds Guideline Creation support tool
‘‘GUIDE’’. Therefore, Doctors Tsuguya Fukui and
Takeo Nakayama of Minds participated as advisors. We
would like to take this opportunity to express out pro-
found gratitude for their unerring advice to the drafting
committee and their efforts in keeping our discussions
focused.
7. Drafting method
First, the drafting committee formulated and listed 101
CQs, of which they adopted 16. For each CQ, we estab-
lished keywords for literature searches. After performing a
literature search, the systematic review team assessed each
piece of literature, the guideline drafting committee made
their recommendations and provided explanations for these
choices, and the boards of each academic society approved
these choices based on public comments in each of their
societies.
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8. Systematic review
We requested literature searches from the Japan Medical
Library Association, on behalf of the systematic review
team, with our searches open to all types of literature
abstracted from the keywords. We searched for literature
published from 1970 to 2014; the databases searched were
PubMed, Ichushi-Web, and the Cochrane Library. Evi-
dence was assessed in accordance with the Minds Treat-
ment Guideline Creation Companion 2014 (Table 1). The
systematic review team performed primary screening and
secondary screening, and drafted an assessment sheet. All
CQ database search results and literature assessment sheets
were posted on each academic society’s website. Please
feel free to refer to these posts as necessary.
9. Drafting of recommendations
Recommendation grades were determined based on the
overall evidence assessments of the systematic review team
with consideration for the trade-offs and balances between
benefits and harm/side effects/risks. These recommenda-
tion grades were determined communally by the guideline
drafting committee via informal consensus; the reasons
underlying the committee’s assessments were recorded.
Recommendation strength was rated on a scale of 1-4 as
described below.
1) Strongly recommended
2) Weakly recommended (suggestion)
3) Weakly advised against (suggestion)
4) Strongly advised against
10. Outside assessment
These guidelines are posted on the websites of the four
academic societies that collaborated to author them (the
Japanese Society of Nephrology, the Japan Society of
Clinical Oncology, the Japanese Society of Medical
Oncology, and the Japanese Society of Nephrology and
Pharmacotherapy); the guidelines were opened to public
comments. All comments and our responses are posted on
each society’s website. Following publication, these
guidelines are scheduled to be assessed by the Appraisal of
Guidelines for Research & Evaluation (AGREE) II
instrument.
11. Issues in drafting of the guidelines
11.1 Assessment of renal function during cancer
drug therapy
There is no established method for assessing renal function
during cancer drug therapy. Although serum creatinine
levels and eGFR, which are used to assess renal function in
real-world clinical settings, are generally recognized to be
somewhat problematic, there is currently no established
method for assessing renal function before and after cancer
drug therapy. The same is naturally true for proxy markers.
11.2 Diversity of anticancer drugs
The term ‘‘anticancer drug’’ covers an extremely large
number of drugs. Each drug exerts different effects on renal
function; discussing these individual effects is not the
purpose of these guidelines. In order to introduce CQs
frequently encountered in real-world cancer treatment, we
have centered our discussion on widely used drugs. Wider
varieties of cancer and drugs will be set aside as topics for
future consideration.
11.3 Relationship to medical economics
For these guidelines, we did not examine issues in medical
economics; therefore, the creation of the guidelines and the
determination of recommendation levels were unaffected
by concerns related to medical economics.
11.4 Reflection of patients’ opinions
It has been recommended that patients’ opinions be
reflected in the creation of these guidelines. However, at
the drafting stage, we were unable to construct a frame-
work for incorporating patients’ opinions.
12. Sources of funding and conflicts of interest
All committee members involved in drafting these guide-
lines have submitted conflict of interest declarations in
accordance with the regulations of their respective aca-
demic societies; these declarations are managed by each
society’s secretariat. These guidelines have been drafted
based purely on scientific grounds and assessment, as well
as public interest. Individual committee members’ conflicts
Table 1 Assessment and definitions of overall evidence strength in
systematic review
A (Strong): Strong confidence in effect estimates
B (Moderate): Moderate confidence in effect estimates
C (Weak): Limited confidence in effect estimates
D (Very Weak): Almost no confidence in effect estimates
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of interests associated with business-academia collabora-
tions are managed properly in compliance with the Policy
of Conflict of Interest in Clinical Research adopted by
academic societies related to internal medicine.
The burden of funding the creation of the present
guidelines was borne by the Japanese Society of
Nephrology and the three related collaborating societies
(the Japan Society of Clinical Oncology, the Japanese
Society of Medical Oncology, and the Japanese Society of
Nephrology and Pharmacotherapy). Funds were used for
the drafting committee members’ transportation expenses,
meeting site expenses, and meal expenses. These funds
were not used for remunerations to the guideline drafting
committee or the systematic review team.
13. Summary of guidelines
13.1 Assessment of renal function
before and after cancer drug therapy
CQ1: Is eGFR recommended for assessment of renal
function for the adjustment of anticancer drug dosages?
Recommendation grade: Weakly recommended (suggestion)
Recommendations
1. When assessing renal function for adjusting anticancer
drug doses, eGFR is recommended if the patient’s
condition is normal for their age and gender, i.e., if the
patient is not malnourished, severely emaciated, or
severely obese.
2. For patients whose muscle mass differs markedly from
standard values due to malnourishment or severe
emaciation, eGFR may not accurately reflect GFR. In
such cases, rather than estimating GFR from serum Cr
levels, combination with another method is recom-
mended, such as measurement of GFR based on urine
collection.
3. For drugs for which doses are fixed regardless of the
patient’s condition, the dose should be adjusted in
accordance with creatinine clearance (Ccr) or eGFR
(mL/min) without correcting for body surface area.
4. For drugs for which the dose is determined by body
surface area in accordance with the patient’s condition,
it is reasonable to use Ccr corrected for body surface
area (per 1.73 m2) or eGFR corrected for body surface
area (mL/min/1.73 m2).
5. In the Cockcroft-Gault equation, Ccr (mL/min) is
calculated using serum Cr values determined with the
Jaffe´ method. When using Cr values determined with
an enzymatic method, as is the standard in Japan, 0.2 is
added to the actual Cr value.
Summary
When assessing renal function for adjusting anticancer
drug doses, eGFR is recommended if the patient’s condi-
tion is normal for their age and gender, i.e., if the patient is
not malnourished, severely emaciated, or severely obese.
For patients whose muscle mass differs markedly from
standard values due to malnourishment or severe emacia-
tion, eGFR may not accurately reflect GFR. In such cases,
rather than estimating GFR from serum Cr levels, combi-
nation with another method is recommended, such as
measurement of GFR based on urine collection. For agents
for which doses are fixed regardless of patient condition,
the dose should be adjusted in accordance with creatinine
clearance (Ccr) or eGFR (mL/min) without correcting for
body surface area. For agents for which the dose is deter-
mined by body surface area in accordance with the
patient’s condition, it is reasonable to use Ccr corrected for
body surface area (per 1.73 m2) or eGFR corrected for
body surface area (mL/min/1.73 m2). In the Cockcroft-
Gault equation, Ccr (mL/min) is calculated using serum Cr
values determined with the Jaffe´ method. When using Cr
values determined with an enzymatic method, as is the
standard in Japan, 0.2 is added to the actual Cr value.
Background and Objectives
In order to conduct anticancer chemotherapy safely and
effectively, it is important to establish appropriate doses to
elicit maximum anticancer effects and minimize side
effects. When renal function is impaired, renally excreted
drugs accumulate in the kidneys, potentially resulting in
serious side effects; therefore, anticancer drug doses must
be adjusted in accordance with renal function.
Estimated GFR is used to assess renal function. Outside
of Japan, GFR is measured based on clearance of chro-
mium (Cr) 51-labeled ethylenediaminetetraacetic acid and
iodine (I)-125 sodium iothalamate, which are the respective
GFR substances EDTA and iothalamate marked with
radioisotopes of chromium and iodine, respectively [1]; in
Japan, the gold standard is inulin clearance [1]. However,
measurement of GFR requires urine collection following
intravenous injection of exogenous clearance substances
marked with inulin or radioactive material, thus making
testing cumbersome. Therefore, Ccr and GFR are typically
estimated based on serum Cr. Although various formulas
have been devised for estimating GFR (Note 1) [2–8], most
of these are intended for patients with chronic kidney
disease and healthy individuals; their efficacy for cancer
patients has not been sufficiently verified.
For patients with renal impairment, dose adjustments are
often based on pharmacokinetic data at the time of clinical
trials. Many trials of dose adjustment tailored to renal
function have used Ccr as calculated from the Cockcroft-
Clin Exp Nephrol (2018) 22:210–244 215
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Gault equation. In 2010, the United States Food and Drug
Administration (FDA) published guidance for pharma-
cokinetics research in patients with impaired renal function
[9]. In addition to the conventional use of Ccr based on the
Cockcroft-Gault equation, the guidance document also
proposed the use of eGFR based on the Modification of
Diet in Renal Disease (MDRD) equation; consequently, for
drugs developed in the future, dose adjustments based on
eGFR may become the norm. Proposed revised guidelines
from the European Medicines Agency (EMA) also describe
assessment of renal function using eGFR based on the
MDRD equation and the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) equation [10]. In
Japan, the Guideline for Clinical Evaluation of Oral
Hypoglycemic Agents published by the Ministry of Health,
Labour and Welfare stipulates that renal function indicators
(eGFR, Ccr, etc.) are recommended for assessment of
clinical trials [11]. Although this guideline is not related to
drug dose adjustments, it shows that eGFR may be used
frequently to assess renal function in clinical trials in Japan
going forward.
The objectives of this draft are to examine existing
findings on renal function assessment in the administration
of anticancer drugs, and to determine the usefulness and
limitations of this assessment in real-world settings.
Commentary
Renal excretion of drugs occurs by glomerular filtration
and tubular excretion; however, because there is no simple
method for quantitatively assessing the drug excretion
function of renal tubules, drug dose adjustments are typi-
cally based on GFR. Likewise, in the development of novel
agents, doses are often established based on GFR or on
Ccr, which reflects GFR. Therefore, GFR has been estab-
lished as the reference for adjusting doses of anticancer
drugs.
Measurement of GFR requires measurement of the
clearance of a substance that is completely filtered by
glomeruli, does not bind to proteins, is not metabolized in
the body, and is not secreted or reabsorbed by renal
tubules. In Japan, the gold standard is inulin clearance;
other countries, however, measure clearance of substances
such as 51Cr-EDTA, I-125 sodium iothalamate, or iohexol.
Although Ccr is sometimes measured in place of GFR,
measurement of Ccr (enzymatic method) yields values
20–30% higher than measurements of GFR based on inulin
clearance. This discrepancy arises from the fact that Cr is
not only filtered by glomeruli, but also secreted by renal
tubules; consequently, GFR & Ccr 9 0.715 [12]. The use
of these methods in clinical settings is constrained by the
need for administration of reagents and urine collection, as
well as a certain length of time before results are reported.
These constraints have resulted in the development of
equations for estimating GFR and Cr based on serum Cr
levels.
Conventionally, drug doses have generally been adjus-
ted using Ccr as estimated with the Cockcroft-Gault
equation. However, because Ccr estimates are higher than
GFR values, several different equations have been devel-
oped for the accurate estimation of GFR; these equations
are now also used to adjust drug doses [13]. Most equations
for calculating eGFR and Ccr were developed for use in
healthy individuals and CKD patients; few such equations
are intended for use in cancer patients. Although the
Wright formula [5], the Martin formula [6], and the Jelliffe
equation [7] are intended for the estimation of GFR in
cancer patients, no method has been developed for esti-
mating GFR specifically in Japanese cancer patients.
Therefore, in regard to the CQ of whether eGFR is rec-
ommended for assessment of renal function for the
adjustment of anticancer drug doses, we conducted litera-
ture searches upon establishing the following two ques-
tions: ‘‘Is eGFR based on serum Cr values an appropriate
substitute for the gold standard of GFR based on clearance
of inulin, 51Cr-EDTA, or I-125 sodium iothalamate?’’ and
‘‘Is eGFR an appropriate substitute for conventional Ccr
calculated with the Cockcroft-Gault equation?’’ We found
12 studies that compared actual GFR to eGFR [14–25],
three studies that compared actual Ccr to eGFR [26–28],
and three studies that compared Ccr as calculated with the
Cockcroft-Gault equation to formulas for eGFR and other
such predictive formulas [29–31].
Results are inconsistent among studies that have
examined the validities of various predictive formulas for
cancer patients; this lack of consistency is assumed to
potentially lead to the overestimation and underestimation
of true GFR within a certain range. Overestimation of GFR
can result in excessive doses of anticancer drugs and
increased risk of side effects, while underestimation of
GFR can lead to insufficient doses of anticancer drugs and
a consequent attenuation of anticancer action. Few studies
have compared actual GFR to eGFR as calculated with the
Japanese Society of Nephrology’s equation in Japanese
cancer patients; thus, further research is desirable.
Research is also necessary to assess the usefulness of
equations for estimating GFR based on serum cystatin C
rather than serum Cr. Most studies compare eGFR to the
gold standard of actual GFR; no studies have examined
therapeutic effects and side effects resulting from admin-
istration of anticancer drugs based on eGFR. Research is
also needed on clinical outcomes comparing the use of
eGFR to the use of actual GFR or the use of Ccr as esti-
mated with the Cockcroft-Gault equation.
At present, eGFR as calculated with the Japanese
Society of Nephrology’s equation yields an approximate
assessment of renal function; if renal function is normal,
216 Clin Exp Nephrol (2018) 22:210–244
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anticancer drug dose adjustment can be considered
unnecessary. However, in the adjustment of doses based on
data from clinical trials, it is safe to use the same renal
function assessment methods and predictive equations. No
matter which predictive equation is used, for patients with
a markedly abnormal condition whose renal function
necessitates anticancer drug dose adjustment or who are
borderline for such adjustment, rather than using eGFR
based on serum Cr value, it is safer to use a combination of
other methods such as actual GFR based on urine collec-
tion (Note 2) and GFR as estimated based on cystatin C.
Although actual GFR based on urine collection and inulin
clearance is preferable, when these are difficult to imple-
ment, GFR can be approximated by multiplying Ccr (en-
zymatic method) by 0.715 [12].
When performing dose adjustments in accordance with
Ccr or GFR, the following point must be noted: when
assessing Ccr and GFR, the decision of whether to correct
for body surface area is related to the method of measuring
serum Cr value using the Cockcroft-Gault equation.
Drug doses are either fixed (mg/day) regardless of the
patient’s condition (body weight and body surface area) or
tailored to the patient’s condition (body weight and body
surface area). In the use of agents for which the dose is fixed
regardless of condition, the dose is adjusted in accordance
with Ccr or eGFR (mL/min) without correcting for body
surface area (Note 3). In regard to this point, the Japanese
Society of Nephrology-edited 2012 CKD Practice Guide
recommends the following: ‘‘When using renally excreted
agents for patients with diminished renal function, renal
function should be assessed with eGFR (mL/min) without
correcting for body surface area, doses should be reduced,
and administration intervals should be prolonged’’ [13]. The
EMA Guideline on the evaluation of the pharmacokinetics
of medicinal products in patients with decreased renal
function also recommends that GFR be measured and
recorded without correcting for body surface area [10]. On
the other hand, in the use of agents for which doses are
established based on body surface area (mg/m2) and body
weight (mg/kg), it is reasonable to use Ccr corrected for
body surface area (per 1.73 m2) or eGFR corrected for body
surface area (mL/min/1.73 m2). Doing so is reasonable
because when using Ccr or GFR per mL/min for correction
in the use of agents for which the dose is adjusted in
accordance with body surface area, the double-counting of
patient condition leads to excessive doses for large-bodied
patients and insufficient doses for small-bodied patients. Ccr
values as calculated with the Cockcroft-Gault equation are
in mL/min without correcting for body surface area, whereas
in the MDRD equation and the Japanese Society of
Nephrology eGFR equation, Ccr values are corrected per
1.73 m2 body surface area (mL/min/1.73 m2). Therefore,
caution is necessary when applying these equations.
In Japan, Cr values are often measured with an enzy-
matic method; however, it must be noted that the Cock-
croft-Gault equation uses Cr values determined with the
Jaffe´ method. In the Jaffe´ method, Cr values are 0.2 mg/dL
higher than Cr values determined with an enzymatic
method; therefore, when calculating Cockcroft-Gault Ccr
using Cr values determined with an enzymatic method, 0.2
is added to the enzymatic test Cr value.
Although some patients who undergo cancer drug ther-
apy for urinary tract tumors possess only one kidney, eGFR
reflects the aggregate function of both kidneys; therefore,
eGFR can also be used for patients with only a single
kidney.
* Note 1: Renal function estimation equations
1) Cockcroft-Gault equation [2]
Estimated Ccr mL=minð Þ ¼ 140  ageð Þ
 body weight kgð Þ
 72  serum Crð Þ
For women, the above value is multiplied by 0.85. The
serum Cr value is determined with the Jaffe´ method. For
serum Cr values determined with an enzymatic method, 0.2
is added to the value.
2) Japanese Society of Nephrology eGFR equation [3]
eGFR mL=min=1:73 m2
  ¼ 194  serum Cr  1:094
 age  0:287
For women, the above value is multiplied by 0.739.
3) MDRD equation [4]
eGFR mL=min=1:73 m2
  ¼ 175  serum Cr  1:154
 ageð Þ  0:203
 0:742 for women½ ð Þ
 1:212 for black patients½ ð Þ
4) Wright formula [5]
eGFR mL=minð Þ ¼ 6580  38:8  ageð Þ½ f
 body surface area  1  0:168½
 men 0; women 1ð Þg = serum Cr
The serum Cr value is determined with the Jaffe´ method.
See Note 2 for the formula for estimating body surface
area.
5) Martin formula [6]
eGFR mL=minð Þ ¼ 163  body weight kg½ f
 1  0:00496  ageð Þ½   1  0:252½
 men 0; women 1ð Þg = serum Cr
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6) Jelliffe equation [7]
Estimated Ccr mL=min=1:73 m2
 
¼ 98  16 age  20ð Þ =20½  = serum Cr
Used for patients aged 20-80 years. For women, the
above value is multiplied by 0.9.
7) CKD-EPI equation [8]
eGFR mL=min=1:73 m2
  ¼ 141  serum Cr = jð Þ a
 0:993 age
j is 0.9 for men and 0.7 for women.
a is -1.209 when serum Cr is larger than j; otherwise, a
is -0.411 for men and -0.329 for women.
For women, the above value is further multiplied by
1.018.
For black patients, the above value is further multiplied
by 1.159.
Note: The unit of serum Cr values is lmol/L in the
Wright formula and Martin formula, and mg/dL in all other
equations
* Note 2: Measurement of actual GFR based on urine
collection
When renal function must be assessed accurately,
measurement of inulin clearance is recommended. There is
a standard method and a simple method for doing so. In the
standard method, saline solution containing 1% inulin is
continuously infused; urine and midpoint blood are col-
lected three times at 30-minute intervals, and the mean of
the three clearances is calculated. In the simple method,
urine is collected for approximately 1 hour under contin-
uous infusion of inulin, and clearance is determined from
blood collected before and after urine collection. The
simple inulin clearance method is shown in a Fig. 1 [13].
Measurement of inulin clearance requires approximately
700 mL of additional fluid intake; thus, care must be taken
to avoid excessive body fluid volume.
* Note 3: GFR not corrected for body surface area
Estimated GFR (mL/min/1.73 m2) predicts GFR for a
standard body surface area; it does not represent actual GFR in
individual patients. In patients whose condition differs greatly
from the standard condition for their age and sex, eGFR over-
estimates or underestimates actual GFR. Therefore, when
establishing drug doses, renal function must be assessed using
GFR without correcting for body surface area (mL/min).
‘‘Not correcting for body surface area’’ means deter-
mining the actual GFR of individual patients rather than
correcting GFR units per 1.73 m2. Values yielded by
estimation equations are already corrected per 1.73 m2
body surface area; therefore, GFR without correcting for
body surface area is calculated as follows after determining
the individual patient’s body surface area:
GFR not corrected for body surface area mL=minð Þ
¼ eGFR mL=min=1:73 m2   1:73
 patients body surface area m2 
The DuBois formula [32], shown below, is a typical
formula for estimating body surface area.
Start of saline including 1 % inulin administration
h/Lm001h/Lm003noitartsinimdaerofeb
-15 min 30 min      45 min      60 min      75 min      90 min      105 min      120 min
Drinking 500 mL Drinking 180 mL
Blood collection Blood collection
Complete urination Urine collection
Fig. 1 Simple inulin clearance method. 1) Complete urine collection
45 minutes after initiating inulin administration. Blood collection
during urination. 2) Urine sampling upon urge to urinate at
approximately 60 minutes of urine collection. Blood collection
during urine sampling. 3) Accurate recording of urine collection time.
4) The blood concentrations of inulin in the two blood samples are
averaged. Japanese Society of Nephrology [13]
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Body surface area m2
  ¼ 0:007184
 body weight kgð Þ0:425
 height cmð Þ0:725
CQ2: Is biomarker-based assessment recommended for
early diagnosis of anticancer drug-induced AKI?
Recommendation grade: Weakly recommended (suggestion)
Recommendation
At present, we cannot strongly recommend biomarker-
based assessment for early diagnosis of anticancer drug-
induced AKI. Although urine protein, urinary albumin,
serum cystatin C, b2 microglobulin, urinary NAG, and
urinary L-FABP can be measured as biomarkers of AKI in
Japan, we cannot strongly recommend these or any other
measurements as biomarkers of AKI.
Summary
In the last several years, several novel biomarkers of AKI
have been reported. However, none of these biomarkers
have yet demonstrated sufficient reliability, sensitivity, or
rapidity in testing and assessment to be used in daily
clinical practice.
Background and Objectives
1) Diagnostic criteria for AKI
In 2004, the Acute Dialysis Quality Initiative proposed the
first uniform diagnostic criteria for AKI. These criteria
focus on serum Cr and urine collection, which can be easily
measured at any facility; the criteria are divided into 5
levels of renal dysfunction described by the acronym
RIFLE (Risk, Injury, Failure, Loss, End-stage kidney dis-
ease) (Table 2) [33]. Furthermore, in 2007, the Acute
Kidney Injury Network (AKIN) proposed its own classifi-
cation (Table 3) [34]. The AKIN classification defines the
diagnostic criteria for AKI as a 1.5-fold increase or an
increase of C 0.3 mg/dL in serum Cr within 48 hours, or
reduced urinary output (\0.5 mL/kg/h) over the span of 6
hours; severity is classified into 3 levels based on the
degree of serum Cr increase and urinary output reduction.
Severity is also assessed based on serum Cr increase and
urinary output reduction within 1 week.
2) Background and objectives
Anticancer drugs frequently result in kidney injury; they
are considered to account for 15% of all cases of drug-
induced kidney injury, the third-leading cause of these
injuries, following antibacterial agents and non-steroidal
anti-inflammatory drugs [35]. Anticancer drugs are also
known to result in AKI; AKI occurred in 36% of a group of
537 patients with acute myeloid leukemia or high-risk
myelodysplastic syndrome who underwent induction
chemotherapy, while 61.7% of patients who developed
ESRD died [36]. A separate study reported an extremely
high mortality rate of 73% among cancer patients with
comorbid AKI [37]. Anticancer drug-induced AKI not only
increases the risk of CKD and ESRD, but also requires
adjustment of anticancer drug doses due to decreased renal
Table 2 Acute Dialysis Quality Initiative (ADQI) AKI diagnostic criteria (RIFLE classification). Crit Care. 2004;8:R204-12. (DOI 10.1186/
cc2872) Bellomo R, et al.; licensee BioMed Central Ltd. 2004. http://ccforum.com/content/8/4/R204
Diagnostic criteria based on serum Cr or GFR Diagnostic criteria based on urine
output (UO)
Risk Increased serum Cr C 1.5-fold the normal value, or GFR decrease[ 25% normal value UO\ 0.5 mL/kg/h for 6 hours
Injury Increased serum Cr C 2-fold the normal value, or GFR decrease[ 50% normal value UO\ 0.5 mL/kg/h for 12 hours
Failure Increased serum Cr C 3-fold the normal value, GFR decrease[75% normal value, or serum Cr
C 4 mg/dL with acute rise C 0.5 mg/dL
UO\ 0.3 mL/kg/h for 24 h, or
anuria for 12 hours
Loss Need for renal replacement therapy for 4 weeks
ESRD Need for dialysis for longer than 3 months
Table 3 AKIN AKI diagnostic criteria (AKIN classification) Crit Care. 2007;11:R31. (DOI 10.1186/cc5713) Mehta RL, et al.; licensee
BioMed Central Ltd. 2007
Stage Diagnostic criteria based on serum Cr Diagnostic criteria based on urine output (UO)
1 Increase in serum Cr C 1.5-2-fold from baseline or C 0.3 mg/dL UO\ 0.5 mL/kg/h for more than 6 hours
2 Increase in serum Cr C 2-3-fold from baseline UO\ 0.5 mL/kg/h for more than 12 hours
3 Increase in serum Cr[ 3-fold from baseline, or serum Cr C 4 mg/dL with acute
increase C 0.5 mg/dL
UO\ 0.3 mL/kg/h for 24 hours, or anuria for
12 hours
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function, thus interfering with the impending administra-
tion of the next anticancer drug. Due to the wide variety of
chemotherapy regimens, AKI presents with a wide variety
of clinical symptoms. Examples of anticancer drug-induced
AKI are shown in Table 4 [38, 39]. A classic example of a
tubular disorder-inducing drug is platinum-based agents,
which primarily result in disorders in the tubulointersti-
tium. For example, cisplatin is known to cause AKI in
approximately one-third of patients [40]. The anti-VEGF
antibody bevacizumab is well known to cause vascular
disorder and induce TMA.
Although the emergence of the RIFLE and AKIN
classifications, which are based on serum Cr and urinary
output, have resulted in significant advances in the
diagnosis of AKI, many issues remain. Serum Cr is
affected by several factors such as age, body weight, sex
differences, other agents, muscle metabolism, protein
intake, and hypervolemia; thus, it is deeply flawed as a
biomarker of AKI [41, 42]. In addition, elevated serum
Cr does not manifest until 48-72 hours after the initial
occurrence of nephrotoxicity, thus hindering prompt
AKI diagnosis and therapeutic intervention [42]. To
compensate for the flaws of serum Cr, the usefulness of
many novel biomarkers of AKI has been examined.
However, the clinical use of novel biomarkers of AKI
still faces high hurdles due to the need to establish
threshold values in accordance with sex differences, age
differences, and primary diseases [43].
The objectives of this guideline are to examine the
latest findings regarding biomarkers for AKI induced by
anticancer drugs, and to determine the usefulness and
limitations of these biomarkers in real-world clinical
settings.
Commentary
The biomarkers discussed in this draft can be assessed
objectively and serve as indicators of pharmacological
responses to biological changes, histological changes, and
therapeutic interventions [44]. Biomarkers of anticancer
drug-induced AKI must be immune to interference from all
types of treatment. Potential roles for biomarkers include:
1) risk assessment, 2) early diagnosis, 3) classification of
disease stage, 4) differential diagnosis, 5) indication of
therapeutic effects, and 6) determination of prognosis.
Anticipation is particularly high for the practical applica-
tion of biomarkers that enable earlier diagnosis than do
serum Cr and eGFR.
The present draft divides biomarkers into two cate-
gories: those that can be used in clinical practice and are
covered by health insurance in Japan, and those that can-
not. Also, in 2010, the Predictive Safety Testing Consor-
tium’s Nephrotoxicity Working Group submitted results
for drug toxicity studies and analyses of biomarker per-
formance to the FDA and the European Medicines Evalu-
ation Agency; these results presented Kidney Injury
Molecule-1 (Kim-1), urinary albumin, urine protein, b2
microglobulin, serum cystatin C, clusterin, and trefoil
factor 3 (TFF-3) as biomarkers related to renal function
safety [45]. Although the objective of this report is limited
to safety assessments, we felt it necessary to discuss the
usefulness of the above 7 biomarkers as biomarkers of
anticancer drug-induced AKI.
Table 4 Examples of anticancer drug-induced AKI (includes only anticancer drugs covered by insurance in Japan) Kidney Int. 2015;87:909-17,
Clin J A Soc Nephrol. 2012;7:1713-21. [2012] Modified from the American Society of Nephrology
Renal vascular abnormalities
Capillary leak syndrome interleukin-2
TMA bevacizumab, gemcitabine, cisplatin, mitomycin C, interferon
Glomerular abnormalities
Minimal change disease interferon, pemetrexed
Focal glomerulosclerosis interferon, pemetrexed, zoledronic acid
Tubulointerstitial abnormalities
Acute tubular necrosis platinum-based agents, zoledronic acid, interferon, pentostatin, imatinib,
pamidronate
Tubulitis (Fanconi syndrome) cisplatin, ifosfamide, azacitidine, imatinib, pamidronate
Magnesium wasting cisplatin, anti-EGFR monoclonal antibodies
Nephrogenic diabetes insipidus cisplatin, ifosfamide, pemetrexed
Syndrome of inappropriate antidiuretic hormone
secretion
cyclophosphamide, vincristine
Acute interstitial nephritis sorafenib, sunitinib
Tubular obstructive nephropathy methotrexate
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1. Biomarkers for which measurement is covered
by health insurance
a) Urinary albumin
Urinary albumin levels increase as a result of enhanced
glomerular permeability and impaired proximal tubular
reabsorption. In fact, short-term and long-term adminis-
trations of nephrotoxic anticancer drugs have been reported
to increase levels of urinary microalbumin [46]. However,
urinary albumin levels are known to increase not only as a
result of AKI, but also due to factors such as fever, exer-
cise, dehydration, diabetes, and hypertension; thus, the
specificity of urinary albumin as a biomarker of AKI is
considered limited [47].
b) Urine protein
In detection of glomerular disease, urine protein is said to
be superior to BUN and serum Cr in terms of diagnostic
performance [48]; however, urine protein is reported to
have low specificity as a biomarker of AKI [49], and its
usefulness has not been established.
c) Serum cystatin C
Cystatin is the most important cysteine protease inhibitor in
the human body. Cystatin C, a 13-kDa protein secreted by
all nucleated cells, is characterized by the fact that it does
not bind to plasma proteins. Therefore, cystatin C is freely
filtered by the renal glomeruli; after being reabsorbed by
the proximal tubules, more than 99% of it is degraded by
the endocytic receptor megalin [50]. Unlike Cr, cystatin C
is not secreted by the renal tubules into urine, and its levels
are not dependent on sex or muscle mass. In patients with
mild to moderate renal impairment, serum cystatin C is
well correlated with GFR [51]; thus, cystatin C can be used
to detect nephrotoxicity at an early stage with greater
sensitivity than serum Cr, thus making serum cystatin C a
potentially useful biomarker of AKI [52]. However, serum
cystatin C is limited in the following two ways: 1) it is
affected by diabetes, high levels of corticosteroids, hyper-
thyroidism, inflammation, hyperbilirubinemia, and hyper-
triglyceridemia [53]; 2) when GFR reaches\ 15 mL/min/
1.73 m2, the increase in serum cystatin C slows and levels
off at 5-6 mg/L [54]. Beno¨hr et al. [55] have demonstrated
that serum cystatin C levels are significantly elevated on
day 5 following cisplatin administration compared to 3
days prior to administration. At present, serum cystatin C
has not been established as a useful biomarker of anti-
cancer drug-induced AKI. Although measurement of serum
cystatin C is covered by health insurance, measurement of
urinary cystatin C is not.
d) b2 microglobulin
b2 microglobulin is a polypeptide comprising 99 amino
acids with a molecular weight of 11,800; it is distributed on
the surface of nucleated cells throughout the body as the L
chain of the major histocompatibility complex HLA class I
antigen. b2 microglobulin passes freely through the
glomerular basement membrane and is almost completely
reabsorbed by the proximal tubule; in tubular disorders,
however, decreased reabsorption leads to increased excre-
tion of b2 microglobulin in urine, thus making b2
microglobulin a potentially useful marker of AKI. In fact,
urinary b2 microglobulin has been reported to increase 4-5
days earlier than does serum Cr in tubular disorders [56].
However, in aciduria and at room temperature, b2
microglobulin is extremely unstable, thus limiting its use-
fulness as a biomarker [57].
e) NAG
In the kidneys, NAG is a glycolytic enzyme present in
lysosomes and produced in the endoplasmic reticula of
proximal tubule cells. Tubular disorders result in increased
excretion of NAG in urine, thus making urinary NAG a
potentially useful marker of AKI; urinary NAG is reported
to demonstrate abnormal values 12 hours to 4 days earlier
than does serum Cr [58]. Goren et al. [59] compared
concentrations of NAG before and after cisplatin admin-
istration in 12 patients. In their investigation, concentra-
tions of NAG increased following cisplatin administration,
reached their peak on day 3, and subsequently decreased.
In an examination of NAG and b2 microglobulin in 8
patients before and after cisplatin administration, Ikeda
et al. [60] reported that b2 microglobulin reached peak
levels on day 3 and decreased to pretreatment levels in 1
week, although only 1 patient demonstrated increased
NAG for 2 weeks. However, urinary NAG activity is
inhibited by many nephrotoxic substances, magnesium, and
endogenous urea [61]. Furthermore, urinary NAG levels
are increased not only in AKI, but also in rheumatoid
arthritis [62], impaired glucose tolerance [63], and hyper-
thyroidism [64]; thus, the specificity of urinary NAG for
AKI is considered low.
f) Urinary L-FABP
Liver fatty acid-binding protein is a fatty acid transport
protein that is expressed in the proximal tubule and that
possesses antioxidant properties [65]. Human L-FABP
possesses a hypoxia-inducible factor 1a responsive ele-
ment; thus, L-FABP expression is induced by hypoxia [66].
Tubular disorders are known to result in increased excre-
tion of L-FABP into urine; patients who develop AKI
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following cardiovascular surgery are reported to demon-
strated an increase in urinary L-FABP immediately after
surgery [67], while a high urinary L-FABP value is
reported to be an independent predictor of AKI [68]. As a
biomarker of AKI, L-FABP compares favorably with Kim-
1, NGAL, and NAG [69]. In Japan, assessment of L-FABP
for the diagnosis of AKI is covered by health insurance.
However, there has been very little investigation of the
usefulness of L-FABP as a biomarker of anticancer drug-
induced AKI in humans; further study is necessary going
forward.
2. Biomarkers for which measurement is
not covered by health insurance
a) Urinary Kim-1
Kidney Injury Molecule-1 is a transmembrane glycoprotein
produced in the proximal tubule during kidney injury; for
12 hours following renal ischemia, excretion of the extra-
cellular domain of Kim-1 into urine is increased [70]. In
animal models of cisplatin-induced nephrotoxicity, levels
of Kim-1 increased earlier than did levels of serum Cr,
indicating that Kim-1 is a useful biomarker of tubular
disorders [71]. In addition, a systematic review reported
fluctuation of Kim-1 within 24 hours of kidney injury [72].
The United States FDA has approved Kim-1 as a marker of
AKI. Tekce et al. [73] compared levels of serum Kim-1 and
urinary Kim-1 prior to cisplatin administration and at days
1, 3, and 5 after cisplatin administration in 8 patients with
AKI and 14 patients without AKI with an eGFR C 90 mL/
min. On day 1, there were no significant differences
between the groups in serum Cr, eGFR, or serum Kim-1;
however, urinary Kim-1 levels were significantly higher in
the AKI group. On day 3, the two groups demonstrated
significant differences in serum Cr, eGFR, and urinary
Kim-1; however, there were no significant differences in
serum Kim-1. Thus, urinary Kim-1 demonstrates potential
as an early marker of cisplatin-induced AKI. However, the
stability of Kim-1 is markedly reduced in urine; thus,
further study of urinary Kim-1 is considered necessary
[74].
b) NGAL
Neutrophil gelatinase-associated lipocalin (NGAL) is a
25-kDa glycoprotein secreted primarily by activated neu-
trophils; under normal circumstances, 100% of NGAL is
reabsorbed by the proximal tubule. In tubular disorders,
NGAL is expressed in the ascending limb of the loop of
Henle and in part of the collecting ducts; due to increased
excretion into blood and urine, NGAL demonstrates
abnormal values 2-4 hours following AKI. A meta-analysis
of more than 2,500 cases found that NGAL is a useful
marker not only for the diagnosis of AKI, but also for renal
prognosis [75]. Peres et al. [76] reported that following the
administration of cisplatin, the group of patients with AKI
demonstrated higher NGAL levels than the non-AKI
group; however, this difference was not significant. Gaspari
et al. [77] also compared NGAL levels between a group of
12 AKI patients and a group of 12 non-AKI patients at 1
and 4 hours and at 1, 2, 3, 7, and 15 days after cisplatin
administration. Although a significant difference between
the AKI group and the non-AKI group in serum Cr was first
observed on day 3 following cisplatin administration, a
significant difference in NGAL was first observed on day 1.
Therefore, NGAL may enable detection of cisplatin-in-
duced AKI earlier than does serum Cr.
c) Clusterin
Clusterin, a 76-80-kDa glycoprotein, is assumed to exert an
anti-apoptotic renoprotective effect in kidney injury. Uri-
nary clusterin is reported to be superior to BUN and serum
Cr in the detection of proximal tubular injury [48]. How-
ever, insufficient research has been done on clusterin in
regard to human AKI, and the usefulness of clusterin as a
biomarker of anticancer drug-induced AKI is unknown.
d) Urinary TFF-3
Urinary excretion of TFF-3 is reduced in AKI. Although
urinary TFF-3 has been demonstrated to be a useful marker
of AKI in animal models, its usefulness in humans has not
been sufficiently examined [78].
e) Endothelin-1
Endothelin-1 is a 21-amino acid protein that possesses a
vasoconstrictor effect; in the kidneys, it is expressed in
mesangial cells and collecting ducts. Takeda et al. [79]
measured urinary endothelin-1-like immunoreactivity/Cr
before and 1 and 2 weeks after cisplatin treatment; these
authors reported that urinary endothelin-1-like immunore-
activity/Cr was significantly increased at 1 and 2 weeks
after cisplatin treatment compared to pretreatment levels.
Following cisplatin treatment, b2 microglobulin/Cr and
endothelin-1-like immunoreactivity/Cr peaked on day 2
and subsequently declined, whereas NAG/Cr peaked on
day 6.
In addition to the above, other substances have also been
examined for their usefulness as biomarkers of AKI, such
as interleukin-18, angiotensinogen, tissue inhibitor of
metalloproteinase-2, and insulin-like growth factor-binding
protein 7 [65].
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The usefulness of various biomarkers has been exam-
ined in animal models [80]; however, there is a significant
dearth of evidence in humans. The following circumstances
account for the near-absence of evidence: 1) The lack of
uniformity in diagnostic criteria for AKI leads to differ-
ences among reports. 2) Although many reports have
examined AKI overall, very few reports have focused on
anticancer drug-induced AKI. 3) For many biomarkers,
evident threshold values have not been established, making
assessment in individual studies difficult. 4) Cancer drug
therapy often combines multiple drugs. Different drugs
induce nephrotoxicity via different mechanisms, while
some drugs (cisplatin, etc.) are assumed to act via multiple
mechanisms; therefore, assessment with a single biomarker
may not be valid (in fact, a study has demonstrated the
usefulness of a combination of multiple biomarkers [49]).
5) When using serum, the possibility cannot be ruled out
that what is being assessed is not AKI, but rather the effects
of anticancer drugs throughout the body. Furthermore, in
such cases, the effects of other factors, such as age and past
history of CKD and other complications, are unknown.
Although biomarkers enhance our understanding of
drug-induced AKI, much remains unknown regarding their
contribution to the diagnosis of AKI. When conducting
anticancer chemotherapy, nephrologists must determine
when biomarkers are necessary, which biomarkers are
useful, how to interpret biomarker data, and how to utilize
biomarker data on an individual basis in treatment for each
patient.
13.2 Prevention of decreased renal function
during cancer drug therapy
(1) Overview
CQ3: Is reduction of anticancer drug doses recom-
mended for mitigating toxicity in patients with
decreased renal function?
Recommendation grade: Weakly recommended (suggestion)
Recommendation
When using drugs that lead to an increased risk of adverse
drug events in patients with decreased renal function, dose
reduction is recommended. However, when the goal is to
cure cancer, doses must ultimately be determined with
consideration of the balance between risks and benefits.
Summary
When using agents that lead to an increased risk of adverse
drug events in patients with decreased renal function, dose
reduction is recommended. However, when the objective is
to cure cancer, doses must ultimately be determined with
consideration of the balance between risks and benefits.
Background and Objectives
The kidneys are an elimination pathway for many anti-
cancer drugs and their metabolites; therefore, renal
impairment can delay the excretion and metabolism of
anticancer drugs, potentially resulting in increased toxicity
and thus necessitating consideration of dose reduction [81].
For patients with decreased renal function, dose reduction
is also sometimes considered for anticancer drugs that are
metabolized in the liver. For example, dose reduction is
considered necessary when irinotecan is administered to
dialysis patients [82–85]. For sorafenib, as well, a drug that
is primarily metabolized in the liver, some believe that
dose reduction should be considered [86]. The present draft
summarizes evidence related to dose reduction and pre-
sents principles for dose reduction for major anticancer
drugs.
Commentary
Answering CQ3 requires studies comparing frequencies of
adverse drug events between normal doses and reduced
doses in patients with decreased renal function; however,
the search formula used in the present guidelines yielded
no relevant literature. Such studies present ethical issues
and are considered difficult to conduct. Much of the
available evidence [87–90] comes from studies that com-
pared the frequencies of adverse drug events in patients
with normal renal function and patients with decreased
renal function (reduced doses) [87–90]. However, there are
very few such studies; thus, the quality of the evidence is
judged to be extremely low (D: Almost no confidence in
effect estimates).
Consideration of the balance between benefits and risks
is particularly important in determining recommendation
levels, but due to the paucity of evidence regarding the
efficacy of treatment with reduced doses, our recommen-
dation is weak.
However, in real-world clinical settings, attempts have
been made to reduce doses in accordance with renal
function and to control plasma drug concentrations; these
attempts have yielded a small number of studies and
guidelines that serve as references. One such attempt with
carboplatin dosing is the Calvert formula, which calculates
doses using target AUC and Ccr as estimated with the
Cockcroft-Gault equation based on the results of a phase I
clinical trial (see CQ10 for details) [91]. Another study has
reported a revised Calvert formula based on data from
Japanese patients [92].
Although there are no comprehensive guidelines
regarding dose reduction methods in Japan, the Japanese
Society of Nephrology and Pharmacotherapy [93] has
presented opinions on dose reduction methods for several
anticancer drugs (Table 5); in addition, there are various
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books with information on dose reduction for anticancer
drugs [94]. Outside of Japan, the United States FDA [95]
and the European Medicines Agency [96] have published
guidelines calling for the inclusion of methods of admin-
istration for patients with decreased renal function in
package inserts for all types of drugs; these publicly
available package inserts may also serve as a reference for
dose reduction.
For anticancer drugs, the therapeutic range and the toxic
range are extremely close to each other. Therapeutic drug
monitoring is considered useful for preventing toxicity in
such cases; in fact, therapeutic drug monitoring has been
proven effective in randomized clinical trials for some
anticancer drugs [97, 98]. However, at present, attempting
to measure blood concentrations of anticancer drugs is not
standard practice.
A realistic desirable approach for patients with
decreased renal function is to begin anticancer drug
administration by referring to the above-mentioned dose
adjustment guidelines, monitor adverse events more clo-
sely than normal, and consider adjusting doses in future
treatment. In patients for whom the objective is to cure
cancer, doses must ultimately be determined in consider-
ation of the balance between risks and benefits.
(2) Platinum-based drugs
CQ4: Is risk factor assessment recommended for pre-
dicting cisplatin-induced AKI?
Recommendation grade: Weakly recommended (suggestion)
Recommendation
Reported predictors of cisplatin-induced AKI include
hypoalbuminemia; smoking; female sex; age (1.03-fold
increase in risk per year of age); concomitant use of other
anticancer drugs; comorbid cardiovascular disease or dia-
betes; advanced cancer; and total cisplatin dose. In order to
prevent cisplatin-induced AKI, risk factors should be
assessed prior to drug administration.
Summary
Reported predictors of cisplatin-induced AKI include
hypoalbuminemia; smoking; female sex; age (1.03-fold
Table 5 Dose reduction methods for major anticancer drugs in patients with decreased renal function
CAPD: continuous ambulatory peritoneal dialysis, CG: Cockcroft-Gault
Although dialyzable, additional 
administration is unnecessary
Hemodialysis (HD),
Peritoneal dialysis (PD) Generic name
Cisplatin [81,93]
20 10>
Normal dose GFR or Ccr (mL/min) 
Moderate renal 
impairment
Severe renal 
impairment
End-stage renal 
failure
70>80 60 50
Although a contraindication, 
reduce dose to 50% following 
dialysis when necessary for 
hemodialysis (HD) patients, and 
reduce dose to 50% for CAPD 
patients
Ccr ≥ 80 mL/min: normally, the initial reference dose is set at a single 
dose of 40, 50, or 60 mg in accordance with body surface area, with 2 
doses per day for 28 consecutive days, followed by cessation for 14 
days. This constitutes 1 course.
Note: 80 > Ccr ≥ 60 mL/min: the dose is reduced 1 level below the 
initial reference dose as necessary; 60 > Ccr ≥ 40 mL: the dose is 
reduced 1 level in principle; 40 > Ccr ≥ 30 mL: the dose is reduced 2 
levels in principle; Ccr < 30 mL: administration is not possible.
Carboplatin [93]
Methotrexate
 [93, 100]
Capecitabine [101]
Tegafur/gimeracil
/oteracil potassium 
[93, 102]
Contraindicated
For patients with serious renal impairment, administration is 
contraindicated due to concern for pronounced side effects such as 
myelosuppression, due to marked delay in renal excretion of gimeracil, 
catabolic enzyme inhibitor of 5-FU, leading to an increase its blood 
concentration.
Single dose of 300-400 
mg/m2; cease for at least 4 weeks. 
This constitutes 1 course.
Calvert formula: Target AUC × (GFR + 25) (mg). For single administration, the initial target AUC is 7 
mg/mL/min; for repeated dose administration, the target AUC is 4-5 mg/mL/min. For dialysis patients, 
substitute 5-10 for GFR.. In Japan, where Cr values are determined with an enzymatic method, the CG equation 
yields high Ccr values, which can easily lead to excessive administration. Recommended measures are to add 
0.2 to the serum Cr value [99] or to use eGFR without correcting for body surface area.
See package insert Reduce dose to 50% Contraindicated due to concern for pronounced side 
effects resulting from delayed excretion
Ccr 30-50 mL/min: 
reduce dose to 75%
See package insert
30
Iofosfamide [103]
See package insert
Ccr 31-45 mL/min: reduce dose to 
50%, 
Ccr 46-60 mL/min: reduce dose to 
75%
Although a contraindication, reduce 
dose to 50% when necessary
See package insert
Ccr 31-45 
mL/min: reduce 
dose to 75%
Ccr 46-60 
mL/min: reduce 
dose to 80%
Ccr ≤ 30 mL/min: reduce dose to 
70%
40
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increase in risk per year of age); concomitant use of other
anticancer drugs; comorbid cardiovascular disease or dia-
betes; advanced cancer; and total cisplatin dose. However,
among existing studies, there is no consistent definition of
AKI, there are no clear threshold values for risk factors,
and there are no established measures for cases with risk
factors. Thus, many issues remain for further investigation.
Background and Objectives
Cisplatin, a key drug in treatment for many types of cancer,
is one of the most commonly used anticancer drugs.
However, cisplatin is known to produce side effects such as
myelosuppression, intestinal toxicity, and neurotoxicity;
another crucial side effect, nephrotoxicity, is a potential
subsequent cisplatin dose-limiting factor. One-third of
patients receiving cisplatin are presumed to have comorbid
AKI [104], which often results in the limitation of subse-
quent doses of cisplatin. Furthermore, AKI sometimes
develops into chronic tubulointerstitial fibrosis and irre-
versible chronic tubulopathy, which may further progress
to CKD [105, 106]. The present draft examines risk factors
that may serve as predictors of cisplatin-induced AKI.
Commentary
Cisplatin-induced renal injury is considered to manifest
primarily as proximal tubular injury, particularly in the S3
segment [107]. Cisplatin is absorbed from the basolateral
surface into cells and injures mitochondrial DNA, thereby
activating apoptosis. Intracellular accumulation of cisplatin
results in inflammation, oxidative stress, and ischemic
injury [105]. Hypomagnesemia is also considered to cause
renal injury. Magnesium is thought to be involved in active
transport mechanisms in the renal tubules. Sobrero et al.
have supposed that hypomagnesemia leads to an increased
concentration of cisplatin in renal tubular cells, thereby
causing proximal tubular injury [108].
In an investigation by de Jongh et al. [109] of
weekly-dose cisplatin for 400 patients with locally
advanced or metastatic cancer, 36% of patients received
cisplatin alone, 49% received cisplatin ? etoposide,
and 15% received cisplatin ? paclitaxel. A total of 116
patients (29%) demonstrated a reduction in Ccr of C
25%, while 29 patients (7%) were unable to continue
cisplatin due to nephrotoxicity. Independent predictors
of post-cisplatin nephrotoxicity as determined by mul-
tivariate analysis were paclitaxel coadministration
(odds ratio [OR] 4.0, p = 0.001), hypoalbuminemia (OR
3.5, p = 0.006), smoking (OR 2.5, p = 0.002), female
sex, and old age. According to age group, the risk of
nephrotoxicity was 26% among patients aged \ 48
years, and increased with age to 35% for patients aged
48-62 years and 41% for patients aged [ 62 years; the
risk of nephrotoxicity increased 1.03-fold per year (OR
1.03, p = 0.007). Regarding gender, the risk of
nephrotoxicity was twice as high for women as for men
(OR 2.0, p = 0.025). Another study reported that cis-
platin excretion capacity is lower in women than in
men [110]; however, the cause of this difference is
unknown. The involvement of smoking in nephrotoxi-
city has been surmised to be the effect of oxidant stress
[111]; however, one possibility that cannot be ruled out
is that smoking causes cardiovascular disease, which
secondarily leads to post-cisplatin nephrotoxicity. Also,
in hypoalbuminemia, an increased concentration of
unbound cisplatin is considered to enhance nephrotox-
icity [109]. The cited study, which defines nephrotoxi-
city as a reduction in Ccr of C 25%, is not strictly an
assessment of predictors of AKI.
In an investigation of 425 patients treated with cisplatin
(total dose 220 mg/m2 [median]), Stewart et al. [112]
reported that in multivariate analysis, the factors that pre-
dicted maximum increases in serum Cr up to 4 weeks after
cisplatin treatment were serum albumin, serum potassium,
body surface area, and number of administrations. How-
ever, this study contains flaws: renal function was assessed
with serum Cr alone, and the authors’ method of assessing
maximum increases in serum Cr up to 4 weeks after cis-
platin treatment is neither a well-established method nor
period for assessment. Furthermore, anticancer drugs were
used in combination with many other drugs; thus, the
degree to which cisplatin contributes to changes in renal
function is unknown.
In an examination of 1,721 patients treated with cis-
platin, Mizuno et al. [113] found, in multivariate analysis,
that cancer stage 4 diagnosis (OR 1.8, p = 0.011) and total
cisplatin dose were risk factors for moderate AKI (1.5-1.9-
fold increase in serum Cr within 7 days of cisplatin treat-
ment), while comorbid cardiovascular disease, comorbid
diabetes mellitus, and cancer stage 4 diagnosis were risk
factors for severe AKI (C 2.0-fold increase in serum Cr
within 7 days of cisplatin treatment).
Several studies have thus reported predictors of AKI.
However, these studies do not present a consistent defini-
tion of AKI, and no studies have utilized the RIFLE or
AKIN classifications. Furthermore, there are no clear
threshold values for risk factors, and there are no estab-
lished measures for cases with risk factors. Thus, many
issues remain for further investigation.
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CQ5: Are divided doses of cisplatin recommended for
preventing nephrotoxicity?
Recommendation grade: Strongly advised against
Recommendation
Divided doses of cisplatin are not recommended for pre-
venting nephrotoxicity, as the significance of this practice
has not been established.
Summary
Divided doses of cisplatin are not recommended for pre-
venting nephrotoxicity, as the significance of this practice
has not been established.
Background and Objectives
The fact that the kidneys are the primary organs that
excrete platinum-based agents, particularly cisplatin, is
related to the nephrotoxicity induced by these agents; this
nephrotoxicity is considered to be caused by tubular
necrosis. Nephrotoxicity is often prevented or alleviated by
hydration via large-volume fluid replacement, or by
administration of magnesium. Although some physicians
prefer to use divided doses of platinum-based agents to
prevent or alleviate nephrotoxicity, some studies with
pediatric cancer patients have reported that nephrotoxicity
is less frequent with continuous drug administration than
with divided doses. The present draft examines the rec-
ommendation level for the current practice of administer-
ing divided doses of cisplatin with the intention of
alleviating nephrotoxicity.
Commentary
At present, there are no articles detailing prospective ran-
domized clinical trials on divided doses of platinum-based
agents with alleviation of nephrotoxicity as the primary
endpoint. No studies have directly examined the nephro-
toxicity prevention effect of divided doses in adult subjects,
while there are only three observation studies that have
compared divided doses of cisplatin to other administration
methods. The content and results of these studies are
summarized below.
Forasteiere et al. compared 5 divided, intermittent doses
of cisplatin (each administered over 20 minutes) to the
same total dose administered via continuous infusion (24
hours) [114]. The subjects were patients with head and
neck cancer; 6 patients received cisplatin 30 mg/m2 via
continuous infusion (24 hours) for 5 days, while another 5
patients received cisplatin 30 mg/m2 via intermittent
intravenous bolus (20 minutes) for 5 days; the two groups
were compared in terms of total platinum concentration,
free platinum concentration, and adverse events. Although
the continuous infusion group demonstrated an extremely
low maximum unbound platinum concentration compared
to the intermittent bolus group, the exposure to unbound
platinum (AUC) was 1.5-2 times higher in the continuous
infusion group. An assessment of subclinical nephrotoxic-
ity based on measurement of urinary excretion of the renal
enzymes NAG and alanine found no differences between
the two groups in nephrotoxicity, or in hearing loss or
nausea/vomiting. In contrast, myelosuppression and hypo-
magnesemia were observed frequently in the continuous
infusion group, suggesting that total platinum exposure
contributes to nephrotoxicity more than does peak con-
centration. Because adverse events in continuous admin-
istration were clinically acceptable, the authors
recommended larger-scale trials with continuous infusion
of cisplatin. However, because this study compared two
forms of divided doses against each other, the merits of
divided doses remain unknown.
Ikeda et al. investigated the optimal administration
method for combined 5-FU ? cisplatin therapy in patients
with gastric cancer and esophageal cancer [115]. The study
compared pharmacokinetic differences (AUC and Cmax) in
12 courses of therapy for 9 subjects. Comparisons were
made among three groups: 4 courses of cisplatin 80 mg/m2
(2 hours), 4 courses of 20 mg/m2 (2 hours) for 5 days, and 4
courses of 100 mg/m2 (120 hours). In all three groups,
5-FU was continuously infused at a dose of 800 mg/m2 (24
hours) for 5 days. The authors concluded that continuous
infusion is the pharmacokinetically optimal administration
method; however, this method has not been recognized to
be superior in terms of adverse events.
Takahashi et al. also compared pharmacokinetics and
nephrotoxicity according to different cisplatin administra-
tion methods (5 divided doses, 24 hours continuous infu-
sion, 12 hours continuous infusion, 6 hours continuous
infusion); they found no differences in clinical adverse
events [116].
The above-cited three studies found no difference in
nephrotoxicity based on the cisplatin administration
method; thus, there is no basis for the active recommen-
dation of divided doses. Therefore, due to the current
absence of appropriately designed studies, there is no basis
for actively recommending divided doses of cisplatin for
the prevention of nephrotoxicity. On the other hand, the
National Comprehensive Cancer Network’s 2014 bladder
cancer guidelines state that divided doses (35 mg/m2 on
days 1 and 2 or days 1 and 8) may be considered for
patients with borderline renal function or minimal dys-
function [117]. However, no references are cited for these
proposed divided doses. In addition, the therapeutic effect
of divided doses is unclear.
Nonetheless, some believe that continuous administra-
tion of cisplatin is safe for preventing and alleviating
226 Clin Exp Nephrol (2018) 22:210–244
123
nephrotoxicity. Erdlenbruch et al. compared pharmacoki-
netics and nephrotoxicity between two groups: a group of 4
pediatric osteosarcoma patients who received continuous
infusion of 120 mg/m2 cisplatin over 72 hours, and a group
of 6 pediatric medulloblastoma patients who received
1-hour bolus infusions of 40 mg/m2 cisplatin per day for 3
consecutive days [118]. The divided dose group demon-
strated a peak concentration of free platinum 19 times that
of the continuous infusion group, as well as a lower min-
imum GFR and a higher rate of persistent nephrotoxicity
within 1 year after the completion of cisplatin therapy. The
authors concluded that continuous administration of cis-
platin is less nephrotoxic than divided doses.
CQ6: Is hydration (‡3 L/day) during cisplatin admin-
istration recommended for mitigating nephrotoxicity?
Recommendation grade: Strongly recommended
Recommendation
Hydration (C3 L/day) during cisplatin administration is
recommended for mitigating nephrotoxicity.
Summary
The nephrotoxicity of cisplatin was established at the
preclinical level (animal trials); therefore, cisplatin dosage
regimens were formulated from the outset using hydration
and other forms of supportive therapy. Consequently,
despite the absence of high-quality evidence from sources
such as randomized clinical trials, hydration is strongly
recommended during cisplatin administration.
Background and Objectives
Platinum-based agents are renally excreted anticancer
agents used to treat various forms of cancer; these agents
are well known to be nephrotoxic. Cisplatin is particularly
nephrotoxic and has thus been examined frequently. The
primary measures for preventing cisplatin nephrotoxicity
are hydration and administration of diuretics. The issues of
fluid replacement volume and the use versus non-use of
diuretics are covered in another CQ and are thus not dis-
cussed here.
Commentary
Answering the present CQ fundamentally requires a ran-
domized clinical trial examining the use versus non-use of
hydration during cisplatin therapy in human subjects;
however, our search formula did not retrieve any such
trials. Most of the existing relevant literature consists of
reviews that discuss nephrotoxicity. As a basis for recom-
mending fluid replacement, one typical review [119] cites
an animal trial [120] that divided dogs into a control group,
a prehydration group, and a mannitol infusion group;
nephrotoxicity was alleviated in the latter two groups.
Many other reviews have also recommended forced
diuresis with hydration and diuretics. Cisplatin was
developed in the 1970s; as a result of the different devel-
opment methodologies of today, as well as the fact that
cisplatin was known early in its development to be
nephrotoxic, the absence of validation studies in human
subjects is considered inevitable. Consequently, the quality
of the evidence is assessed as extremely poor (D: Almost
no confidence in effect estimates).
In the evidence for various existing cancer drug thera-
pies, implementation plans prescribe normal hydration
when using cisplatin. For other platinum-based agents
(carboplatin, etc.), hydration is not typically prescribed.
The Japanese package insert for cisplatin states in the
dosage section that hydration is to be performed before,
during, and after administration; however, the package
insert for carboplatin does not contain such instructions. In
the United States as well, the package insert for cisplatin
calls for hydration, whereas the package insert for carbo-
platin does not (rather, it specifies that, unlike with cis-
platin, massive hydration and forced diuresis are normally
not to be performed).
In consideration of the above information, and of the
balance between benefits and risks, hydration during
cisplatin administration is strongly recommended.
Hydration is not recommended during administration of
other platinum-based agents such as carboplatin. In the
past, hydration during cisplatin administration com-
monly consisted of approximately 2 L saline solution or
half-normal saline solution prior to cisplatin and C 1 L
saline solution or half-normal saline solution after cis-
platin. In regard to ‘‘short hydration’’, which reduces this
hydration volume and uses oral rehydration, please see
CQ7.
CQ7: Is short hydration recommended during cisplatin
administration?
Recommendation grade: Weakly recommended (suggestion)
Recommendation
When administering cisplatin on an outpatient basis, short
hydration is recommended with consideration of renal
function, performance status (PS), and age. However,
performing short hydration safely requires sufficient oral
rehydration and establishment of sufficient urinary output.
Short hydration is intended for patients who, from day 0 to
day 3 of chemotherapy, can consume a normal amount of
food and undergo an additional *1,000 mL of hydration
per day. When oral rehydration is insufficient, it is neces-
sary to modify the environment to enable rapid hydration
via intravenous infusion.
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Summary
When administering cisplatin, short hydration is recom-
mended with consideration of renal function, PS, and age.
Performing short hydration safely requires sufficient oral
rehydration; short hydration is intended for patients who,
from day 0 to day 3 of chemotherapy, can consume a
normal amount of food and undergo an additional *1,000
mL of hydration per day. When oral rehydration is insuf-
ficient, the environment must be modified to enable rapid
hydration via intravenous infusion. In addition, short
hydration requires establishment of sufficient urinary out-
put via diuretics (mannitol or furosemide), supplementation
of magnesium and potassium, and confirmation of serum
electrolyte levels.
Background and Objectives
Before and after administration of cisplatin, hydration must
be performed in order to prevent nephrotoxicity. In Japan,
standard practice is to replace 1,000-2,000 mL fluid over
the course of C 4 hours before and after cisplatin and to
administer cisplatin diluted with C 500-1,000 mL infusion
solution over the course of C 2 hours. However, this
hydration is performed over a long period of time and
requires hospitalization. A number of studies have exam-
ined methods of hydration for preventing cisplatin-induced
nephrotoxicity. Here, we have examined the safety of short
hydration via 2,000-2,500 mL fluid replacement over the
course of approximately 4 hours.
Commentary
In 2007, Tiseo et al. [121] reported the results of a retro-
spective two-center observational study regarding the
safety of high-dose cisplatin (C 75 mg/m2) administered
with short hydration. Following administration of approx-
imately 2,000 mL saline solution and furosemide over the
course of 4 hours on the day of cisplatin administration,
nephrotoxicity resulted in withdrawal of chemotherapy in 5
of 107 subjects (4.6%); among these 5 subjects, 2
demonstrated Grade 2 nephrotoxicity according to National
Cancer Institute Common Toxicity Criteria. In Japan,
Horinouchi et al. [122] and Hotta et al. [123] have con-
ducted small-scale prospective trials with patients who
received 75 mg/m2 and 60 mg/m2 cisplatin, respectively.
With short hydration incorporating potassium, magnesium,
and mannitol, elevations in serum Cr of Grade 2 or higher
(based on the reference range upper limit in the Common
Terminology Criteria for Adverse Events ver. 4.0) occurred
in 2.2% (1/44) and 0% (0/46) of subjects, respectively. In
all other literature we assessed [124–130], compared to
conventional hydration, short hydration was found not to
increase the incidence of nephrotoxicity and was concluded
to be safe; the results of these studies were judged to be
consistent. The short hydration method assessed in the
present CQ is as follows: a total of approximately 1,600-
2,500 mL fluid is replaced over the course of approxi-
mately 4 hours; potassium and magnesium are supple-
mented; and urinary output is established via diuretics
(furosemide and mannitol). In contrast, the United States
National Comprehensive Cancer Network presents a
chemotherapy order template of a total of 1,000-3,000 mL
hydration before and after cisplatin administration at a rate
of 250-500 mL/h for many carcinomas [131]. In Japan, the
Japan Lung Cancer Society and the Japanese Society of
Medical Oncology have created a guide that mentions short
hydration, stating that short hydration can be performed
safely if the target patients are limited to those who meet
certain criteria [132]. These target patients fulfill condi-
tions such as the following: age\75 years, serum Cr value
below the center’s reference value, Ccr C 60 mL/min, PS
of 0-1 on the Eastern Cooperative Oncology Group scale,
no pleural effusion or ascites, cardiac function capable of
withstanding approximately 500 mL/h hydration (left
ventricular ejection fraction C 60% on echocardiography,
etc.), completion of appropriate antiemetic therapy, and
ability to receive approximately 1,000 mL/day oral
hydration from day 0 to day 3 of cisplatin administration.
Therefore, consciousness of disease and assurance of
adherence are important when selecting patients. In addi-
tion, in the event of serious side effects or insufficient
water intake, fluid replacement should be performed at a
center that can adapt rapidly to such circumstances. All of
the target studies were observational studies; therefore, the
quality of the overall evidence was initially graded as C
(weak). There were judged no serious problems with risk of
bias, indirectness, inconsistency, imprecision, or publica-
tion bias, all of which downgrade the quality of evidence.
In addition, intervention effects, dose-response gradient,
and confounders, all of which improve the quality of evi-
dence, were judged not to apply; therefore, the overall
quality of evidence was ultimately graded as C (weak).
CQ8: Are diuretics recommended for preventing cis-
platin-induced nephrotoxicity?
Recommendation grade: Weakly recommended (suggestion)
Recommendation
We cannot definitively recommend diuretics for preventing
cisplatin-induced nephrotoxicity. Such a preventive effect
has not been proven in small-scale randomized clinical
trials; therefore, there is no basis for recommending
diuretics to achieve this effect. Nevertheless, diuretics are
used to prevent nephrotoxicity during cisplatin treatment,
which has been widely performed since the 1970s. The
efficacy and safety of diuretics for preventing
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nephrotoxicity have been confirmed in large-scale clinical
trials of cisplatin and other therapies. Therefore, there is
also no basis for rejecting the use of diuretics to prevent
cisplatin-induced nephrotoxicity.
Summary
We cannot definitively recommend diuretics for preventing
cisplatin-induced nephrotoxicity. Such a preventive effect
has not been proven in small-scale randomized clinical
trials; therefore, there is no basis for recommending
diuretics to achieve this effect. Nevertheless, diuretics are
used to prevent nephrotoxicity during cisplatin treatment,
which has been widely performed since the 1970s. The
efficacy and safety of diuretics for preventing nephrotoxi-
city have been confirmed in large-scale clinical trials of
cisplatin and other therapies. Therefore, there is also no
basis for rejecting the use of diuretics to prevent cisplatin-
induced nephrotoxicity.
Background and Objectives
High-dose cisplatin administration was first reported to be
possible with the combined use of hydration and diuretics
in the 1970s. Since then, the osmotic diuretic mannitol and
the loop diuretic furosemide have been used to prevent
nephrotoxicity in the administration of cisplatin. Here, we
examine whether these diuretics are effective for prevent-
ing cisplatin-induced nephrotoxicity.
Commentary
A phase I clinical trial for cisplatin has demonstrated that
nephrotoxicity is a dose-limiting factor [133]. Hydration
and diuretics have been used in attempts to rapidly excrete
toxic platinum metabolites and reduce their duration of
contact with the renal tubule in order to alleviate nephro-
toxicity. However, pharmacokinetic analysis has shown
that diuretics do not affect the half-life of free platinum
following cisplatin administration and are considered to
reduce the urinary excretion rate and increase serum plat-
inum concentration [134, 135]. Even if diuretics are
effective in preventing nephrotoxicity, the mechanism of
this effect is not sufficiently understood.
Hayes et al. were the first to report that fluid replacement and
mannitol alleviate cisplatin-induced nephrotoxicity. High-dose
cisplatin (120 mg/m2) was administered to 60 patients with the
combined use of hydration and mannitol. The 52 patients who
were analyzed demonstrated only temporary increases in serum
Cr; no serious nephrotoxicity was observed. Serum Cr
increased by\ 2 mg/dL in almost all patients; although 10
patients demonstrated greater increases, 9 of those patients
demonstrated reduced renal function at baseline and were at
high risk for nephrotoxicity [136]. Following this report,
diuretics have been used in the majority of subsequent clinical
trials for therapies that include cisplatin.
Ostrow et al. conducted the first trial comparing man-
nitol and furosemide. Twenty-two patients with advanced
cancer resistant to existing therapies received 100 mg/m2
cisplatin. The subjects were assigned to one of two groups;
one group received 37.5 g mannitol by 6-hour infusion,
while the other group received 40 mg furosemide by
intravenous injection 60 minutes prior to treatment. All
subjects underwent hydration with 1 L normal saline fol-
lowing cisplatin administration. Nephrotoxicity (defined as
Ccr B 50 mL/min or serum Cr[2 mg/dL) occurred in 28%
of the 22 courses in the mannitol group and 19% of the 25
courses in the furosemide group. Mean Ccr values in the
mannitol group and the furosemide group were 34 mL/min
and 26 mL/min, respectively. Although the mannitol group
demonstrated a tendency toward more severe nephrotoxi-
city, the difference was not statistically significant.
Therefore, the interpretation is that neither diuretic was
demonstrated to be superior [137].
In a prospective randomized phase II trial, Al-Sarraf
et al. compared the incidence of post-cisplatin nephrotox-
icity between hydration alone and hydration ? mannitol.
Nephrotoxicity occurred following initial cisplatin admin-
istration in 30% of patients who received hydration only
and in 15% of patients who received hydration ? mannitol.
The overall incidence of nephrotoxicity in the hydration
only group and the hydration ? mannitol group was 39%
and 32%, respectively. Thus, mannitol demonstrated a
prevention effect against cisplatin-induced nephrotoxicity
in the initial administration of cisplatin; however, this
effect was not evident in subsequent administrations [138].
Santoso et al. conducted a randomized comparative trial
to compare the cisplatin-induced nephrotoxicity prevention
effects of hydration (500 mL normal saline), hydration ?
furosemide (40 mg), and hydration ? mannitol (50 g).
Forty-nine patients with gynecologic cancers underwent
therapy with 75 mg/m2 cisplatin ? paclitaxel or 5-FU and
were randomly assigned to one of the three above-de-
scribed combination therapies. A total of 15 women were
assigned to the hydration only group, while 17 were
assigned to the hydration ? furosemide group and 17 were
assigned to the hydration ? mannitol group. The three
groups demonstrated nearly equal Ccr at baseline. How-
ever, following cisplatin therapy, Ccr (± standard devia-
tion) in the hydration only group, the hydration ?
furosemide group, and the hydration ? mannitol group was
80.4 (±33.5), 81.4 (±23.3), and 60.6 (±26.8) mL/min,
respectively; thus, the hydration ? mannitol group
demonstrated a result significantly inferior to that of the
other two groups [139]. Several issues have been high-
lighted in relation to this trial: the trial was discontinued
due to poor outcomes in the hydration ? mannitol group,
the sample size was small, the dose of mannitol was larger
than in previous trials, and urine collection for Ccr lacked
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rigor, among other issues. Thus, despite being a random-
ized comparative trial, its quality is lacking.
Therefore, although diuretics have been widely used
since the 1970s to prevent nephrotoxicity induced by
platinum-based agents, no randomized comparative studies
have clearly demonstrated that diuretics are effective to
that end, and there is no sufficient basis to recommend
diuretics for that purpose. The European Society of Clinical
Pharmacy Special Interest Group on Cancer Care states in
their recommendations on the prevention of cisplatin
nephrotoxicity that there is no reason to recommend the use
of diuretics [140]. However, diuretics have been widely
used in the administration of cisplatin for many years, and
this approach has been used to create evidence for various
therapies; thus, the safety of diuretics in cisplatin admin-
istration is well established. In short hydration as well,
which has been attempted in recent years, the use of
diuretics is presumed, and they have been reported to be
safe. Therefore, without proof that diuretics pose evident
risks, there is little basis to advise against the use of these
agents.
CQ9: Is magnesium recommended for preventing cis-
platin-induced nephrotoxicity?
Recommendation grade: Weakly recommended (suggestion)
Recommendation
Administration of magnesium, which can be expected to
prevent hypomagnesemia, has been indicated to affect
renal function favorably; therefore, administration of
magnesium is recommended for preventing nephrotoxicity.
Summary
Prophylactic administration of magnesium can be expected
to prevent hypomagnesemia and alleviate nephrotoxicity
following the administration of cisplatin.
Background and Objectives
Due to enhanced excretion primarily from the kidneys as
well as intestinal toxicity, cisplatin administration fre-
quently results in hypomagnesemia, which has been
reported to potentially cause nephrotoxicity. Therefore,
prophylactic administration of magnesium is anticipated to
alleviate nephrotoxicity.
Commentary
In our searches for studies comparing nephrotoxicity in the
use versus non-use of magnesium in patients receiving
high-dose cisplatin, we found two randomized comparative
trials and one retrospective analysis [141–143].
Willox et al. randomly assigned 17 cancer patients (16
patients with testicular cancer and 1 patient with an ovarian
dysgerminoma) scheduled to receive cisplatin into a
magnesium treatment group and a non-magnesium treat-
ment group; the non-magnesium group subsequently
demonstrated significant tubular damage (high NAG value)
[141]. Bodnar et al. conducted a double-blind, randomized
comparison of magnesium administration and non-admin-
istration (placebo) in ovarian cancer patients scheduled to
receive cisplatin; the magnesium group subsequently
demonstrated significantly favorable GFR compared to the
placebo group [142]. Although both of the above studies
indicate that prophylactic administration of magnesium
affects renal function favorably, the sample sizes were
small, and the endpoints and statistical hypotheses were
unclear. Therefore, although magnesium can be anticipated
to prevent nephrotoxicity, this preventive effect has not
been definitively verified.
However, prophylactic administration of magnesium is
inferred to prevent hypomagnesemia and consequently
alleviate adverse reactions such as nephrotoxicity, while
adverse reactions induced by prophylactic administration
of magnesium are minor; considering these points, pro-
phylactic administration of magnesium is currently
recommended.
CQ10: Is carboplatin dose setting based on renal
function recommended?
Recommendation grade: Strongly recommended
Recommendation
In adult cancer patients receiving carboplatin, there is
insufficient evidence to prove that the method of setting
doses based on renal function following the establishment
of a target AUC increases therapeutic effects and reduces
side effects compared to the general method of determining
doses based on body surface area. However, the setting of
doses based on renal function is both reasonable and
widespread in daily clinical practice.
Summary
In adult cancer patients receiving carboplatin, there is
insufficient evidence to prove that the method of setting
doses based on renal function following the establishment
of a target AUC increases therapeutic effects and reduces
side effects compared to the general method of determining
doses based on body surface area. However, the setting of
doses based on renal function is both reasonable and
widespread in daily clinical practice. Therefore, we graded
our recommendation as ‘‘strong’’.
Background and Objectives
The platinum-based agent carboplatin is almost completely
excreted from the kidneys following administration;
therefore, its pharmacokinetics can be predicted based on
GFR. Furthermore, AUC, an indicator of drug exposure
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volume in the body, is closely correlated with hematotox-
icity and antitumor effect. Consequently, it is now wide-
spread practice to set carboplatin doses based on GFR after
establishing a target AUC. In many cases, GFR is substi-
tuted by Ccr. The present draft examines the validity of the
routine clinical practice of setting carboplatin doses based
on renal function.
Commentary
Carboplatin is a platinum-based agent with a broad anti-
tumor spectrum that primarily includes gynecologic cancer
and lung cancer. Because carboplatin is almost completely
excreted from the kidneys following administration, its
pharmacokinetics can be predicted based on GFR [144].
Furthermore, AUC, an indicator of drug exposure volume
in the body, is strongly correlated with thrombocytopenia
and other forms of hematotoxicity, which limit carboplatin
doses; AUC is also strongly correlated with antitumor
effect. Therefore, individual differences in the side effects
and therapeutic effects of carboplatin can be explained by
individual differences in AUC arising from pretreatment
GFR [145]. Setting carboplatin doses based on GFR after
establishing a target AUC minimizes individual differences
in AUC, which can consequently be expected to reduce the
risks of serious hematotoxicity and undertreatment. Based
on this idea, Calvert et al. created a formula for setting
carboplatin doses based on GFR; this formula, called the
Calvert formula, remains widely used in daily clinical
practice today [146].
Calvert formula : dose mg½ 
¼ target AUC mg=mL  min½ 
 GFR mL=min½  þ 25ð Þ
To calculate doses, the previously established target
AUC and the patient’s GFR are entered into the Calvert
formula. Based on clinical trials, AUC is set at 5-7; how-
ever, analysis of a model for ovarian cancer patients
demonstrates that while the antitumor effect of carboplatin
nearly plateaus at an AUC of 5-7, thrombocytopenia and
other forms of hematotoxicity are enhanced as AUC
increases [147]. Similar formulas for calculating carbo-
platin doses based on renal function have been created by
Egorin et al. [148, 149] and Chatelut et al. [150]; however,
the Calvert formula remains the most widely used due to its
simplicity. In any case, setting dosages based on renal
function is reasonable. However, no clinical trial has
prospectively examined the setting of doses based on renal
function from the perspective of increasing therapeutic
effects and reducing side effects in comparison to typical
methods based on body surface area; thus, the evidence for
setting doses base on renal function is insufficient.
In the process of creating the Calvert formula, the
investigators employed actual GFR based on clearance of
EDTA labeled with 51Cr, a radioisotope of chromium. In
Japan, the gold standard for GFR is inulin clearance;
although measurement of inulin clearance is covered by
health insurance, the procedure is cumbersome, and thus,
Ccr is often used instead in daily clinical practice. How-
ever, not only does serum Cr undergo glomerular filtration,
approximately 20-30% of it is secreted from the renal
tubules; consequently, Ccr yields higher values than does
GFR, a point which requires caution. The serum Cr values
used to calculate Ccr are measured with the Jaffe´ method
and an enzymatic method. The Jaffe´ method is affected by
non-specific substances in serum; therefore, the measured
value of serum Cr is approximately 0.2 mg/dL higher than
the true serum Cr value. However, in calculations of Ccr,
this measurement error is cancelled out by the difference
with GFR resulting from tubular secretion; therefore, in
effect, Ccr calculated with serum Cr as determined by the
Jaffe´ method approximates GFR. With an enzymatic
method, on the other hand, serum Cr measurements are
precise, and Ccr values are higher than GFR values. Con-
sequently, the Calvert formula, which uses Ccr as a sub-
stitute for GFR, engenders a risk of excessive carboplatin
dosing. Since the mid-1990s, most medical centers in Japan
have used the enzymatic method, whereas the United States
and Europe have used the Jaffe´ method until recently.
Caution is necessary when interpreting clinical trials of
carboplatin conducted outside Japan. One proposed mea-
sure is to add 0.2 to enzymatic method-based serum Cr
values when calculating Ccr [151, 152]. When GFR is
used, it is calculated with the Japanese Society of
Nephrology’s GFR estimation formula (eGFR) without
correcting for body surface area (see CQ1). However,
many Japanese clinical trials currently use Ccr calculated
from enzymatic method-based serum Cr values in place of
GFR. When evidence from these trials is used in clinical
practice, regardless of the presence of evident bias between
the actual AUC and the target AUC, what is effectively
being used is GFR estimated with the same methods as in
the relevant trials. However, considering the objective of
individualized patient doses based on renal function, renal
function should be accurately assessed from the clinical
trial stage in order to prevent bias between actual AUC and
target AUC.
In the United States, since 2010, serum Cr has been
measured by isotope dilution mass spectrometry, which are
as accurate as the enzymatic method. Accordingly, estab-
lishing an upper limit for the GFR used in the Calvert
formula (125 mL/min) is recommended to avoid the
excessive carboplatin dosing that would result from over-
estimation of renal function. In gynecology, for extremely
low serum Cr, a lower limit (0.7 mg/dL) is sometimes
established. With these methods, it must be noted that
actual AUC is larger than target AUC in the majority of
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patients, while actual AUC is smaller than target AUC in
some patients with favorable renal function.
The ‘‘GFR?25’’ component of the Calvert formula
corresponds to total carboplatin clearance; ‘‘GFR’’ corre-
sponds to renal clearance, while the constant ‘‘25’’ corre-
sponds to non-renal clearance. Non-renal clearance
depends primarily on an individual’s physical size. The
Calvert formula was created in the United Kingdom; when
using the Calvert formula for Japanese individuals, who are
physically smaller on average than Caucasians, the pro-
portion of non-renal clearance increases relative to GFR,
particularly in patients with severely decreased renal
function, thereby potentially leading to excessive carbo-
platin dosing [153].
Measurement of Ccr requires urine collection (typically
for 24 hours); thus, estimates calculated based on serum Cr
values are sometimes used as a substitute for GFR. For-
mulas for estimating Ccr include the Cockcroft-Gault
equation and the Jelliffe equation. Formulas for estimating
GFR in the United States and Europe include the MDRD
equation, the CKD-EPI equation, and the Wright formula;
for Japanese patients, the previously described GFR esti-
mation formula (eGFR) is used (see CQ1). When using
these formulas, the patient’s background (e.g., racial dif-
ferences and pathologies) and the serum Cr measurement
method must be noted. Furthermore, these formulas pre-
sume that serum Cr is stable; when renal function fluctuates
markedly (such as in the acute phase of renal failure) or
when muscle mass is greatly reduced (such as in sarcopenia
or undernutrition), renal function will be overestimated.
(3) Other agents
CQ11: Is urine alkalinization recommended for pre-
venting nephrotoxicity in high-dose methotrexate ther-
apy with leucovorin rescue?
Recommendation grade: Strongly recommended
Recommendation
Urine alkalinization is recommended for preventing
nephrotoxicity in methotrexate with leucovorin rescue.
Summary
In methotrexate with leucovorin rescue, in addition to urine
alkalinization and diuresis via sufficient hydration, moni-
toring of blood methotrexate levels is recommended. In
addition, increased doses and prolonged administration of
leucovorin in accordance with serum methotrexate levels
are recommended.
Background and Objectives
Methotrexate with leucovorin rescue was developed in the
1970s; supportive therapies such as urine alkalinization and
diuresis via sufficient hydration were generally established
by the 1990s. The present draft re-examines this method
based on recent findings.
Commentary
More than 90% of methotrexate is excreted from the
kidneys. In animal experiments, methotrexate nephro-
toxicity has been shown to arise from the accumulation of
methotrexate or its metabolite 7-OH-MTX in the renal
tubules. The solubility of methotrexate and its metabolites
depends on urinary pH; this solubility is considered to
increase five- to eight-fold with an increase in pH from
6.0 to 7.0 [154]. Methotrexate with leucovorin rescue was
developed in the 1970s with the following theoretical
basis: when high-dose (generally C 500-1000 mg/m2)
methotrexate is administered, the methotrexate is pas-
sively incorporated into cancer cells; after a certain
amount of time has elapsed, leucovorin is administered as
a methotrexate antidote and is passively incorporated by
healthy cells capable of doing so, thereby rescuing those
cells. Methotrexate with leucovorin rescue has been
demonstrated as effective against osteosarcoma, acute
leukemia, and malignant lymphoma; however, in the
1970s, the frequency of drug-related deaths was at a high
rate of approximately 6% [155]. The pathological expla-
nation for these drug-related deaths emphasized the fol-
lowing: methotrexate nephrotoxicity results in delayed
excretion of methotrexate itself, thereby aggravating
myelosuppression and other serious adverse events [155].
Subsequently, in addition to diuresis with urine alkalin-
ization [156] and sufficient hydration [157], monitoring of
blood methotrexate levels has become widespread, as
have increased doses and prolonged administration of
leucovorin based on serum methotrexate levels [158]. In
accordance with these technical improvements, deaths
related to methotrexate with leucovorin rescue have
decreased; data for 3,887 cases of osteosarcoma aggre-
gated in 2004 showed a rate of deaths related to
methotrexate with leucovorin rescue of 0.08% [159].
Based on the above, although there is no evidence from
randomized comparative trials, the establishment of uri-
nary output through urine alkalinization and sufficient
hydration are recommended to prevent nephrotoxicity in
methotrexate with leucovorin rescue. However, in the
above-cited 2004 data, nephrotoxicity Grade C 2 (WHO
criteria, serum Cr levels 1.5-3.0 9 upper limit of normal)
was observed in 68 patients (1.8%); the methotrexate with
leucovorin rescue-related mortality rate among these
patients was 4.4%, thus remaining high [159]. Increased
doses of leucovorin are reported to be effective for
delayed excretion of methotrexate resulting from
nephrotoxicity [160].
232 Clin Exp Nephrol (2018) 22:210–244
123
The efficacy of recombinant enzymes for directly
degrading methotrexate in plasma has recently been
reported in a prospective trial [161] and a retrospective
analysis [162]; these recombinant enzymes have been
approved in the United States, but not in Japan.
Methotrexate is a small molecule with a molecular weight
of only 454.44 and thus can be removed by hemodialysis.
On the other hand, approximately 50% of methotrexate
binds to proteins, and its volume of distribution is tens of
liters; in 4 hours, hemodialysis removes only 10.8% of
methotrexate (according to drug information). However,
the use of high-flux membranes in hemodialysis has been
reported in case studies to remove methotrexate more
efficiently [163, 164], thus making this technique worthy of
consideration as a therapeutic approach.
On the other hand, in combination chemotherapy that
includes standard-dose methotrexate, i.e., cyclophos-
phamide, methotrexate, and 5-FU (CMF) for breast cancer
and methotrexate, vinblastine, doxorubicin, and cisplatin
(M-VAC) for urothelial carcinoma, there is no definitive
evidence showing that leucovorin and urine alkalinization
are useful for preventing nephrotoxicity. In addition, the
combined use of non-steroidal anti-inflammatory drugs in
combination chemotherapy that includes standard-dose
methotrexate is reported to exacerbate adverse events;
therefore, methotrexate should not be used in combination
with non-steroidal anti-inflammatory drugs [154].
CQ12: Is withdrawal or reduction of angiogenesis
inhibitors recommended when proteinuria is observed?
Recommendation grade: Strongly recommended
Recommendation
When proteinuria is observed during administration of
angiogenesis inhibitors, withdrawal or reduction of these
drugs is recommended upon consideration of the grade of
proteinuria and of the risks/benefits of continued drug
therapy.
Summary
Administration of angiogenesis inhibitors requires regular
measurement of blood pressure, urinalysis for early
detection of hypertension and proteinuria, and proactive
administration of antihypertensive agents for sufficient
control of blood pressure. If proteinuria manifests, tem-
porary withdrawal of angiogenesis inhibitors or continued
treatment with reduced doses are reasonable options;
however, in the case of grade 1 proteinuria, for patients
with advanced cancer, another option is to continue treat-
ment upon consideration of the risks and benefits. When
proteinuria is grade 2 or higher, angiogenesis inhibitors are
temporarily withdrawn or reduced, and the patient is trea-
ted by a nephrologist as necessary.
Background and Objectives
Angiogenesis inhibitors, which are clinically applied in the
treatment of various carcinomas, inhibit tumor angiogen-
esis primarily by suppressing the VEGF pathway. The
actions and adverse events of angiogenesis inhibitors differ
from those of cytotoxic anticancer drugs. Proteinuria, like
hypertension, is an adverse event that occurs during treat-
ment with angiogenesis inhibitors [165]. Proteinuria and
microalbuminuria have been demonstrated to be indepen-
dent risk factors for renal disease and cardiovascular dis-
ease [166]; thus, when proteinuria manifests during
administration of angiogenesis inhibitors, appropriate
management is necessary. There are many different types
of angiogenesis inhibitors, each of which is indicated for a
different carcinoma and has a different treatment regimen.
Angiogenesis inhibitors are administered upon initiation of
drug therapy for carcinomas that in most cases occur in a
solitary kidney, such as advanced renal cell carcinoma.
Furthermore, angiogenesis inhibitors are sometimes
administered alone and also sometimes used as part of
multidrug therapy. With this diverse background, the
incidence of proteinuria during administration of angio-
genesis inhibitors has been determined to differ for each
individual agent [165]. According to Japanese special drug
use surveillance, during the administration of bevacizumab
in 2,696 cases of advanced colorectal cancer, proteinuria
occurred in 4.60% of cases; proteinuria was serious in
0.11% of these cases [167]. The incidence of proteinuria
during the administration of sunitinib in 2,141 cases of
advanced renal cell carcinoma and gastrointestinal stromal
tumors was 1.59%, versus an incidence of 1.20% in
advanced renal cell carcinoma and 2.98% in gastrointesti-
nal stromal tumors [168]. During the administration of
sorafenib in 3,335 cases of advanced renal cell carcinoma,
the incidence of proteinuria was 0.71%, with no cases of
serious proteinuria reported [169]. In a phase II clinical
study of 64 Japanese patients with cytokine-refractory
metastatic renal cell carcinoma, proteinuria occurred in
58% of patients, 9% of whom developed serious protein-
uria of grade 3 or higher [170].
Commentary
Angiogenesis inhibitors, i.e., VEGF pathway inhibitors,
result in proteinuria during treatment; although the precise
mechanism of onset of this adverse effect has not been
determined, the presumed mechanism is a breakdown of
glomerular structure and filtration function originating from
the inhibition of VEGF production by podocytes [171].
Angiotensin-converting enzyme inhibitors and ARBs dilate
efferent arterioles, reduce intraglomerular pressure, and
reduce proteinuria; therefore, administration of angiogenesis
inhibitors must involve regular measurement of blood
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pressure, urinalysis for early detection of proteinuria, and
proactive administration of antihypertensive agents for suf-
ficient control of blood pressure [165].
While the incidence of proteinuria is different for each
individual angiogenesis inhibitor, the risk of proteinuria is
considered to be dose-dependent [172, 173]. Thus, when
proteinuria manifests, reduction or temporary withdrawal
of angiogenesis inhibitors are practical options. In fact, in a
clinical trial that investigated the therapeutic effects of
various molecularly targeted agents, many patients who
demonstrated grade 2 or higher proteinuria during treat-
ment were able to resume treatment following dose
reduction or withdrawal [174]. When advanced cancer
patients with limited outcomes develop grade 1 proteinuria
during treatment with angiogenesis inhibitors, withdrawal
or reduction is not always necessary; rather, the decision
must be based on an examination of the benefits/risks of
continued drug therapy and on the individual patient’s
wishes. However, cases of nephrotic syndrome have been
confirmed during treatment with various types of angio-
genesis inhibitors [175–177]. In cases in which proteinuria
worsens despite temporary withdrawal or reduction of
angiogenesis inhibitors, referral to a nephrologist should be
considered [165].
CQ13: Is reduction of bisphosphonates and anti-
RANKL antibodies recommended for patients with
decreased renal function?
Recommendation grade: Strongly recommended
Recommendation
Reduction of bisphosphonates is recommended for patients
with decreased renal function. However, reduction of anti-
RANKL antibodies is not recommended for patients with
decreased renal function.
Summary
Reduction of bisphosphonates is recommended for patients
with decreased renal function. However, reduction of anti-
RANKL antibodies is not recommended for patients with
decreased renal function.
Background and Objectives
Injectable bisphosphonates have been established as useful
for improving malignancy-induced hypercalcemia and
inhibiting skeletal-related events associated with bone
lesions resulting from multiple myeloma or bone metas-
tases from solid tumors (defined as pathologic fracture,
radiotherapy for bone lesions, surgery for bone lesions,
spinal cord compression, and hypercalcemia). The primary
bisphosphonates used in treatment for malignancies in
Japan are zoledronic acid and pamidronate. Pamidronate is
approved for malignancy-induced hypercalcemia and
osteolytic bone metastases from breast cancer, whereas
zoledronic acid is approved for malignancy-induced
hypercalcemia and bone lesions resulting from multiple
myeloma or bone metastases from solid tumors. In Europe,
intravenous ibandronate is approved for the inhibition of
bone metastasis-related events. One known adverse event
associated with bisphosphonates is nephrotoxicity; the
present draft examines the necessity of dose reduction in
accordance with renal function.
Commentary
High-dose (90-360 mg/month) pamidronate has been
reported to induce glomerulosclerosis and acute tubular
necrosis, as well as to accelerate acute renal failure and
nephrotic syndrome [178]. A subsequent examination of
dosage and administration time found that nephrotoxicity
was mild when pamidronate 90 mg was administered over
the course of C 3 hours, while a phase III trial found no
significant pamidronate-induced nephrotoxicity compared
to placebo. Based on these results, the American Society of
Clinical Oncology (ASCO) guidelines were revised to
specify that when pamidronate 90 mg is administered over
the course of C 2 hours, reduction of the pamidronate dose
is unnecessary even when Ccr is 30-60 mL/min; the
guidelines also specify that when Ccr is \ 30 mL/min,
further prolongation of pamidronate administration time
(4-6 hours) or pamidronate dose reduction is recommended
[179, 180].
Several phase III trials of zoledronic acid for breast
cancer with osteolytic lesions, multiple myeloma, lung
cancer, and other solid tumors began with a protocol of 4
mg or 8 mg administered over the course of 5 minutes;
however, the group that received 8 mg over 5 minutes
demonstrated a high incidence of nephrotoxicity, thereby
necessitating a two-stage protocol amendment. First, the
administration duration was extended from 5 minutes to 15
minutes; second, the 8 mg dose was reduced to 4 mg. These
amendments reduced the incidence of nephrotoxicity
induced by zoledronic acid to a rate equal to that induced
by placebo or by pamidronate (the control group)
[181–185]. In 2005, Novartis Pharmaceuticals filed a
package insert revision with the FDA stating that for
patients with decreased renal function (Ccr 30-60 mL/min),
the dosage of zoledronic acid was to be reduced to achieve
the same AUC as that for patients with a Ccr of 75 mL/min
(specifically, doses of 3.5 mg, 3.3 mg, and 3.0 mg for
patients with a Ccr of 50-60 mL/min, 40-49 mL/min, and
30-39 mL/min, respectively). The revised ASCO guideli-
nes specify the following: the recommended dose and
duration for zoledronic acid is 4 mg over C 15 minutes;
when Ccr is 30-60 mL/min, the dose should be reduced in
accordance with the recommendation in the package insert;
and when Ccr is\30 mL/min, zoledronic acid should not
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be administered. In a retrospective analysis of 220 patients,
Shah et al. reported that when zoledronic acid doses were
adjusted as recommended in the package insert, patients
with decreased renal function demonstrated the same
incidence of acute renal failure (as an adverse event asso-
ciated with zoledronic acid) as patients with normal renal
function [186].
Ibandronate, for which an intravenous formulation is
approved in Europe, is used to inhibit associated skele-
tal-related events associated with bone metastasis (in
Japan, ibandronate is approved only in oral form for
osteoporosis). Ibandronate is considered to be associated
with the lowest incidence of nephrotoxicity of all intra-
venous bisphosphonates [187] However, the package
insert recommends that when Ccr is [ 50 mL/min,
infusion time should be extended from 15 minutes to 1
hour; and when Ccr is\ 30 mL/min, the dose should be
reduced from 6 mg to 2 mg.
Anti-RANKL antibodies were developed to treat bone
metastasis; in a phase III trial, anti-RANKL antibodies
were significantly superior to zoledronic acid in inhibiting
skeletal-related events. Renal impairment did not occur;
thus, dose adjustments in accordance with renal function
are considered unnecessary [188]. However, patients with
Ccr \ 30 mL/min and ESRD patients requiring dialysis
were excluded from the trial; therefore, it is necessary to
consider the potential onset of serious hypocalcemia and to
assess the suitability of anti-RANKL antibodies carefully
for patients with severe renal impairment.
(4) Maintenance dialysis patients
CQ14: Is dialysis therapy recommended for drug
removal following cisplatin administration in mainte-
nance dialysis patients?
Recommendation grade: Weakly advised against
(suggestion)
Recommendation
The majority of cisplatin binds to tissue and proteins and
remains in the body even if dialysis is performed, with the
resultant potential for a post-dialysis rebound. Therefore,
dialysis therapy for drug removal is not recommended
following cisplatin administration for maintenance dialysis
patients, regardless of timing.
Summary
The majority of cisplatin binds to tissue and proteins and
remains in the body even if dialysis is performed, with the
resultant potential for a post-dialysis rebound. Therefore,
dialysis therapy for drug removal is not recommended
following cisplatin administration for maintenance dialysis
patients, regardless of timing. However, this is only an
expert opinion based on case reports; further clinical study
is necessary to close the evidence-to-practice gap.
Background and Objectives
Due to concerns regarding accumulated toxicity following
cisplatin administration, ESRD patients sometimes
undergo dialysis for drug removal. In the present draft, we
assess the efficacy of dialysis therapy for drug removal
following cisplatin administration.
Commentary
Cisplatin rapidly binds to plasma proteins upon entering
the blood, thereby undergoing conversion from unbound
cisplatin (free Pt) to protein-bound cisplatin (&total Pt).
One side effect of cisplatin is nephrotoxicity; dialysis
patients, whose renal function has already been eliminated,
may instead face problems such as myelotoxicity and
peripheral neuropathy.
Aside from case reports, there are very few systematic
studies of the pharmacokinetics of cisplatin in dialysis
patients. In their investigation of the pharmacokinetics of
cisplatin in five patients who developed gastric cancer
during maintenance dialysis, Miyakawa et al. reported the
following results. When cisplatin was administered con-
currently with the initiation of dialysis, the concentration of
free Pt in blood rapidly decreased and was below mea-
surable levels following dialyzer use; the concentration of
total Pt fluctuated relatively sharply in the early stage and
subsequently decreased gradually. When dialysis was ini-
tiated 1 hour after cisplatin administration, changes in
concentrations of free Pt and total Pt in blood were con-
sidered to be the same as when cisplatin and dialysis were
initiated simultaneously. However, the study does not
specify which patients began cisplatin and dialysis imme-
diately and which patients began dialysis 1 hour after
administration of cisplatin [189]. In the same year as the
above study, Miyakawa et al. reported on the pharma-
cokinetics of cisplatin in 2 gastric cancer patients under-
going maintenance dialysis; however, it is unclear whether
these 2 patients were also included in the other study [190].
In all case reports, aside from a report by Inozume et al.
stating that, ‘‘In order to maximize the effect of the key
drug cisplatin, we elected to perform dialysis the day after
cisplatin’’ [191], dialysis was initiated 30 minutes to 1 hour
following the administration of cisplatin. Without allowing
a certain interval following cisplatin administration, free Pt
will be eliminated from the blood by dialysis before it can
bind to plasma proteins, thus greatly reducing the antitumor
effect. Patients with normal renal function who receive
cisplatin demonstrate a biphasic pattern in which the blood
concentration of cisplatin increases sharply in the early
stage (a-phase), then gradually decreases (b-phase). This
pattern is also observed in patients with chronic renal
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failure; the a-phase is considered to be result of the entry of
cisplatin into tissue [192]. The b-phase is the result of
excretion of cisplatin from the kidneys; in patients with
renal failure, this reduction in the blood concentration of
cisplatin is either diminished or completely absent. This
biphasic pattern is also observed in reports in which dial-
ysis is initiated 30 minutes to 1 hour following cisplatin
administration.
Cisplatin administered in vivo binds to proteins in
plasma and tissue in a short time, after which it is not
dialyzed; therefore, in 3.5 to 4 hours of dialysis, only
approximately 10% of cisplatin is removed [193, 194].
Most cisplatin removed from the body is free Pt; the
majority of cisplatin binds to tissue and proteins, thus
remaining in the body even when dialysis is performed. A
post-dialysis rebound results in a renewed increase in free
Pt in blood [191, 195–200]. In addition, as the volume of
accumulated cisplatin increases, the rate of cisplatin
removed by dialysis further decreases [198, 201].
The above-cited studies demonstrate that although most
free Pt can be removed by dialysis, the majority of cisplatin
binds to tissue and proteins and thus remains in the body
even when dialysis is performed, thereby potentially
resulting in a post-dialysis rebound and a consequent
renewed increase in cisplatin concentration. Therefore, the
answer to the present CQ can be considered to be, ‘‘Even
when dialysis is performed following cisplatin adminis-
tration, not only is the cisplatin removal rate roughly a
mere 10%, a rebound phenomenon occurs; therefore,
regardless of timing (whether immediately after cisplatin or
30 minutes to 1 hour after cisplatin), dialysis is not rec-
ommended for the removal of cisplatin’’. However, this is
an only an expert opinion based on case reports; further
clinical study is necessary to close the evidence-to-practice
gap. When cisplatin is administered to dialysis patients, a
50-75% dose reduction is recommended [202, 203]. When
dialysis is performed following cisplatin administration,
caution is necessary regarding cisplatin accumulation.
(5) Particular comorbidities
CQ15: Is rasburicase recommended for preventing
tumor lysis syndrome?
Recommendation grade: Strongly recommended
Recommendation
Rasburicase is recommended for preventing tumor lysis
syndrome.
Summary
The suitability of rasburicase for preventing tumor lysis
syndrome (TLS) has been described according to risk in the
Japanese Society of Medical Oncology’s Tumor Lysis
Syndrome Practice Guidance [204]; rasburicase has also
been reported to reduce the need for hemodialysis. Ras-
buricase reduces uric acid levels, prevents nephropathy,
and is effective in preventing TLS.
Background and Objectives
Rasburicase is a recombinant version of urate oxidase that
rapidly metabolizes uric acid to allantoin. Compared to uric
acid, allantoin is much more soluble in urine; this meta-
bolism thus rapidly reduces uric acid levels in blood.
Administration of rasburicase requires caution regarding
the following three points: 1) rasburicase is an enzyme
preparation and may thus trigger hypersensitivity reactions;
2) antibody formation has been reported, thereby rendering
repeated administration is not recommended; 3) rasburic-
ase is contraindicated in patients with glucose-6-phosphate
dehydrogenase deficiency. The present draft examines
whether rasburicase is recommended for the prevention of
TLS.
Commentary
The suitability of rasburicase for preventing TLS has been
described according to risk in the Japanese Society of
Medical Oncology’s Tumor Lysis Syndrome Practice
Guidance [204]; for high-risk and moderate-risk patients,
in cases in which uric acid levels continually increase
despite the use of allopurinol and febuxostat, or in cases in
which hyperuricemia is observed at diagnosis, rasburicase
should be administered or at least considered [204]. The
TLS preventive effect of rasburicase has been demon-
strated in a phase III study that randomly assigned subjects
at high risk for TLS to rasburicase only (0.20 mg/kg/day,
days 1-5), rasburicase plus allopurinol (rasburicase 0.20
mg/kg/day, days 1-3; allopurinol 300 mg/day days 3-5), or
allopurinol only (300 mg/day, days 1-5). In comparison to
the allopurinol only group, the rasburicase only group
demonstrated a significantly lower incidence of laboratory
TLS1 [205]. In a number of other studies conducted in
children, rasburicase significantly reduced uric acid levels
compared to allopurinol [206, 207]. Regarding the
nephropathy preventive effect of rasburicase, a systematic
review of multiple clinical trials conducted in leukemia and
lymphoma patients found that hemodialysis was performed
for 0-2.8% of patients who used rasburicase, versus 15.9-
25.0% of patients who did not use rasburicase; thus, the use
of rasburicase tended to reduce the need for hemodialysis
[208]. Rasburicase has also been shown to reduce uric acid
levels in patients at high risk for TLS in a number of
randomized comparative trials [209, 210]. The above-cited
studies demonstrate that rasburicase reduces uric acid
1 Based on Cairo-Bishop diagnostic criteria [211].
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levels, prevents nephropathy, and is effective for prevent-
ing TLS.
CQ16: Is plasmapheresis recommended for anticancer
drug-induced thrombotic microangiopathy?
Recommendation grade: Weakly advised against
(suggestion)
Recommendation
Due to the absence of definitive evidence, plasmapheresis
is currently not recommended for anticancer drug-induced
thrombotic microangiopathy (TMA). Although plasma-
pheresis has been observed to inhibit the progression of
TMA-induced renal impairment in a handful of isolated
cases, the efficacy of plasmapheresis for this purpose has
not been properly assessed and therefore is currently not
recommended.
Summary
Plasmapheresis is currently not recommended for anti-
cancer drug-induced TMA due to the dearth of reliable
evidence on its efficacy for this purpose. Although there are
several case series and cross-sectional studies regarding
mitomycin C, these studies have been no assessments of
therapy with plasmapheresis alone. Because, plasma-
pheresis is often performed following hemodialysis or is
combined with drug therapy based on anti-platelet drugs
and steroids. On the other hand, regarding TMA-induced
renal impairment, several reports have only stated that
plasmapheresis inhibited further worsening of renal func-
tion. In addition, plasmapheresis is often combined with
hemodialysis. Thus, the usefulness of plasmapheresis
against drug-induced TMA has not truly been assessed.
Background and Objectives
Thrombotic microangiopathy is a disorder that presents with
thrombocytopenia, microangiopathic hemolytic anemia, and
organ dysfunction. Classical TMAs include thrombotic
thrombocytopenic purpura (TTP) and Shiga toxin-induced
hemolytic-uremic syndrome (HUS), in both of which
activity of a disintegrin-like and metalloproteinase with
thrombospondin type 1 motifs 13 (ADAMTS13) is reduced.
However, there is a great deal that remains unknown
regarding the pathology of TMA, while the pathology of
TMA is diverse; therefore, in 2013, all TMAs other than TTP
and HUS were defined as atypical hemolytic-uremic syn-
drome (aHUS), for which diagnostic criteria were created
[212]. While TTP can present with both congenital and
acquired ADAMTS13 deficiency, most cases involve
acquired deficiency, in which anti-ADAMTS13 autoanti-
bodies are involved. Therefore, plasmapheresis is the first-
line treatment for acquired TTP. The objectives of plasma-
pheresis are ADAMTS13 replenishment; removal of anti-
ADAMTS13 antibodies; and removal of unusually large von
Willebrand factor multimers (UL-vWFM), which are mul-
timers composed of a hemostatic factor called von Wille-
brand factor. For HUS, plasmapheresis has not been
established as effective and is used primarily as supportive
therapy. Plasmapheresis is also used for aHUS induced by
complement system abnormalities; however, due to the
diverse etiology of aHUS, the efficacy of plasmapheresis for
this purpose has not been established. Drug-induced TMA
includes TTP caused by production of immunological
autoantibodies against ADAMTS13 associated with ticlo-
pidine and other antiplatelet drugs; for this form of TTP,
plasmapheresis is effective. On the other hand, calcineurin
inhibitors such as cyclosporine and tacrolimus are not
associated with ADAMTS13 deficiency; these drugs con-
sidered to cause aHUS, which primarily induces vascular
endothelial injury without decreasing ADAMTS13 activity,
for which plasmapheresis is often ineffective. Many cases of
drug-induced TMA are considered to present with a
pathology resembling that of aHUS; however, the detail
mechanism of drug-induced TMA remains poorly under-
stood. Anticancer drugs that induce TMA include mitomycin
C, cisplatin, bleomycin, gemcitabine, pentostatin, and suni-
tinib [213].
Although plasmapheresis is combined with antiplatelet
drugs and steroids to treat TMA, there is no established
treatment. The present draft examines the efficacy of
plasmapheresis for anticancer drug-induced TMA.
Commentary
In regard to the efficacy of plasmapheresis for mitomycin
C-induced TMA, a case series of 4 patients [214] reported the
results of antiplatelet drugs ? plasmapheresis (3-4 L)
administered 5-7 times over 1-2 weeks. Two patients
demonstrated rapid improvement in platelet count, red blood
cell count, and other hematologic parameters, as well as a
tendency toward recovery of renal function within 6 weeks.
Another patient continued to demonstrate decreased renal
function following plasmapheresis; however, over the fol-
lowing C 4 months, renal function gradually improved. The
last patient, despite demonstrating an increase in platelet
count following plasmapheresis, did not show improvement
in renal function and subsequently died. No relationship was
demonstrated in these patients between overall mitomycin C
dose and TMA onset; thus, no definitive conclusion was
reached about the usefulness of plasmapheresis. In some
cases, plasmapheresis is combined with antiplatelet drugs
(e.g., dipyridamole and sulfinpyrazone) or hemodialysis
(conditions unknown); therefore, the effects of plasma-
pheresis monotherapy are difficult to assess.
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In regard to cancer-associated HUS, a cross-sectional
study of patients in a national registry with hematocrit
B 25%, platelet count \ 10 9 104 lL, and serum Cr
C 1.6 mg/dL (accounting for 99% of patients receiving
mitomycin C and 68% of patients receiving 5-FU) [215]
found that of the 37 patients who underwent plasma-
pheresis, 11 patients (30%) responded to treatment, while
26 patients (70%) either did not respond to treatment or
worsened. In a case series of 12 patients who developed
TMA following mitomycin C-containing chemotherapy
regimens [216], all patients demonstrated renal failure at
the time of diagnosis; although 2 of these patients
demonstrated low serum Cr values of 1.8 mg/dL and 2.7
mg/dL, the remaining 10 patients demonstrated serum Cr
values of 3.4-9.6 mg/dL. Six of these patients underwent
2 L plasmapheresis 3 times over the course of 1-2 weeks
while also receiving antiplatelet drugs or steroids.
However, only 1 of these patients responded to
plasmapheresis; this patient was also receiving steroids,
azathioprine, and dipyridamole.
In a cross-sectional study of breast cancer patients,
plasmapheresis was performed 2-49 times (median 46 times)
to treat TMA which had developed following high-dose
chemotherapy with cyclophosphamide, cisplatin, and car-
mustine ? autologous bone marrow stem cell transplantation
[217]. High-dose chemotherapy was performed for 581
patients, 15 of whom (2.6%) developed TMA; 4 of these
patients survived. Of the 15 patients who developed TMA, 12
underwent steroid therapy ? plasmapheresis. Survival fol-
lowing TMA diagnosis was 2-76 days (median 41 days); 3 of
the 4 survivors had undergone plasmapheresis a mean 50
times.
In a case series of 9 patients who developed TMA among
a total of 2,586 patients receiving gemcitabine [218], the
median time to development of TMA in the 9 patients was 8
months (3-18 months) following a total gemcitabine dose of
19.2 g/m2 (9-56 g/m2). Six of the patients survived, while 3
died. Of these 9 patients, 5 underwent plasmapheresis.
Among these 5 patients, 2 died, while the other 3 developed
chronic renal failure; of these latter 3 patients, 2 required
dialysis. Of the 3 patients whose renal function recovered,
none underwent plasmapheresis; however, the report does
not explain the details of this recovery.
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